Document:

Collaboration Agreement

 EXHIBIT 10.41 
 COLLABORATION AGREEMENT 
 between 
 MONOGRAM BIOSCIENCES, INC. 
 and

 PFIZER INC. 
 Dated
as of May 5, 2006 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

							
	1.	 	Definitions	  	1
		 	1.1	 	Additional Facility	  	1
		 	1.2	 	Action	  	2
		 	1.3	 	Affiliate	  	2
		 	1.4	 	Agreement	  	2
		 	1.5	 	Anticipated Launch Date	  	2
		 	1.6	 	Applicable Reimbursement Amount	  	2
		 	1.7	 	Arrange for Delivery	  	2
		 	1.8	 	Assay	  	2
		 	1.9	 	Business Day	  	2
		 	1.10	 	Change of Control	  	2
		 	1.11	 	CLIA	  	2
		 	1.12	 	CMS	  	2
		 	1.13	 	Code	  	2
		 	1.14	 	Collaboration Security Agreement	  	2
		 	1.15	 	Commercial Assay	  	3
		 	1.16	 	Commercially Reasonable Efforts	  	3
		 	1.17	 	Consolidator Performance Standards	  	3
		 	1.18	 	Continuation Remedy	  	3
		 	1.19	 	Continuation Remedy Term	  	3
		 	1.20	 	Costs of Services	  	3
		 	1.21	 	Costs of Services Cap	  	3
		 	1.22	 	Costs of Services Estimate	  	3
		 	1.23	 	Cost of Services True-Up Amount	  	3
		 	1.24	 	Costs of Services Reconciliation	  	3
		 	1.25	 	Coverage	  	3
		 	1.26	 	CPT	  	3
		 	1.27	 	Customer	  	3
		 	1.28	 	Diligent Efforts	  	3
		 	1.29	 	DOJ	  	3
		 	1.30	 	Effective Date	  	3
		 	1.31	 	Encumbrance	  	3
		 	1.32	 	Established Country	  	4
		 	1.33	 	Established Assay Criteria	  	4
		 	1.34	 	Qualifying Samples	  	4
		 	1.35	 	Ex-US Country	  	4
		 	1.36	 	Ex-US Territory	  	4
		 	1.37	 	FDA	  	4
		 	1.38	 	FTC	  	4
		 	1.39	 	GAAP	  	4
		 	1.40	 	Governmental Approval	  	4
		 	1.41	 	Governmental Authority	  	4
		 	1.42	 	IND	  	4
		 	1.43	 	Indemnified Party	  	5
		 	1.44	 	Indemnifying Party	  	5
		 	1.45	 	Infrastructure Plan	  	5

  

 i 

							
		 	1.46	  	ISC	  	5
		 	1.47	  	JSC	  	5
		 	1.48	  	Launch	  	5
		 	1.49	  	Launch Date	  	5
		 	1.50	  	Laws	  	5
		 	1.51	  	Losses	  	5
		 	1.52	  	Major Markets	  	5
		 	1.53	  	Medicare Allowable Amount	  	5
		 	1.54	  	Monogram	  	5
		 	1.55	  	Monogram Confidential Information	  	5
		 	1.56	  	Monogram Copyrights	  	5
		 	1.57	  	Monogram Facility	  	6
		 	1.58	  	Monogram Intellectual Property	  	6
		 	1.59	  	Monogram Patent Rights	  	6
		 	1.60	  	Monogram Technology	  	6
		 	1.61	  	Monogram Trademarks	  	6
		 	1.62	  	National Limitation Amount	  	6
		 	1.63	  	NDA	  	6
		 	1.64	  	Note	  	6
		 	1.65	  	Note Agreement	  	6
		 	1.66	  	Parties	  	6
		 	1.67	  	Patent Rights	  	6
		 	1.68	  	Patient	  	7
		 	1.69	  	Performance Standards; Certain Breach Remedies	  	7
		 	1.70	  	Person	  	7
		 	1.71	  	Pfizer	  	7
		 	1.72	  	Pfizer Agent	  	7
		 	1.73	  	Pfizer Confidential Information	  	7
		 	1.74	  	Pfizer Facility	  	7
		 	1.75	  	Pfizer Facility Term	  	7
		 	1.76	  	Pfizer Product	  	7
		 	1.77	  	Pfizer Technology	  	8
		 	1.78	  	Privacy Regulations	  	8
		 	1.79	  	Reimbursement Approval	  	8
		 	1.80	  	Regulatory Approval	  	8
		 	1.81	  	Regulatory Authority	  	8
		 	1.82	  	Regulatory Filing	  	8
		 	1.83	  	Representatives	  	8
		 	1.84	  	Sample	  	8
		 	1.85	  	Sample Handling Guidelines	  	8
		 	1.86	  	Senior Executive	  	8
		 	1.87	  	SOP	  	8
		 	1.88	  	Successful Test	  	9
		 	1.89	  	Tangible Material	  	9
		 	1.90	  	Technology	  	9
		 	1.91	  	Term	  	9

  

 ii 

							
		  	1.92	  	Third Party	  	9
		  	1.93	  	Third Party Claim	  	9
		  	1.94	  	US Territory	  	9
		  	1.95	  	Construction.	  	9
			
	2.  	  	Supply of Assay in the US Territory	  	9
		  	2.1	  	US Territory Supply	  	9
		  	2.2	  	Reimbursement Responsibility	  	9
		  	2.3	  	Fulfillment Standards for the US Territory	  	10
		  	2.4	  	Supply of Other Assays.	  	10
			
	3.	  	Supply of Assay In the Ex-US Territory	  	11
		  	3.1	  	Ex-US Supply	  	11
		  	3.2	  	Reimbursement Responsibility	  	11
		  	3.3	  	Regulatory Responsibility	  	11
		  	3.4	  	Sales and Marketing Responsibility	  	11
		  	3.5	  	Compensation.	  	12
			
	4.	  	Governance Structure of the Assay Collaboration.	  	13
		  	4.1	  	Joint Steering Committee.	  	13
		  	4.2	  	Decision-Making Authority.	  	13
		  	4.3	  	Meetings	  	14
		  	4.4	  	Minutes	  	14
		  	4.5	  	JSC Functions and Powers	  	15
		  	4.6	  	Independence	  	16
			
	5.	  	Monogram’s Ex-US Infrastructure and Operating Costs.	  	16
		  	5.1	  	Ex-US Country Infrastructure	  	16
		  	5.2	  	Monogram Infrastructure Roles and Responsibilities.	  	16
		  	5.3	  	Infrastructure Plan Implementation Process.	  	17
		  	5.4	  	Front End Transfers	  	18
		  	5.5	  	Logistic Responsibility in Ex-US Countries	  	18
		  	5.6	  	Employees; Contractors	  	18
		  	5.7	  	Ex-US Infrastructure Costs and Operating Costs	  	18
		  	5.8	  	Payments	  	19
			
	6.	  	Invoicing and Payments	  	19
		  	6.1	  	Invoicing	  	19
		  	6.2	  	Payment Method	  	19
		  	6.3	  	Taxes.	  	19
		  	6.4	  	Interest	  	20
		  	6.5	  	Advances	  	20
			
	7.	  	Pfizer and Customer Education.	  	20
		  	7.1	  	Pfizer Education	  	20
		  	7.2	  	Customer Education	  	20
		  	7.3	  	Materials; Call Center	  	21

  

 iii 

							
	8.	  	Regulatory Affairs; Compliance with Law.	  	21
		  	8.1	  	Regulatory Filings and Approvals.	  	21
		  	8.2	  	Compliance with Law.	  	21
		  	8.3	  	Licensure	  	22
		  	8.4	  	Excluded Provider	  	22
			
	9.	  	Ownership of Materials and Intellectual Property	  	22
			
	10.	  	Confidentiality	  	23
		  	10.1	  	Treatment of Confidential Information	  	23
		  	10.2	  	Authorized Disclosure	  	23
		  	10.3	  	Publicity	  	24
		  	10.4	  	Data Ownership; Publications	  	24
		  	10.5	  	Agreement Filing	  	25
			
	11.	  	Additional Or Pfizer Testing Facility	  	25
		  	11.1	  	Establishment of Additional Testing Facility	  	25
		  	11.2	  	Operation of Additional Testing Facility.	  	26
		  	11.3	  	Reimbursement	  	26
		  	11.4	  	Abandonment	  	27
		  	11.5	  	Monogram Option	  	27
		  	11.6	  	Alternative Arrangements	  	27
			
	12.	  	Performance Standards; Certain Breach Remedies	  	27
		  	12.1	  	Forecasting.	  	27
		  	12.2	  	Performance Standards	  	28
		  	12.3	  	Pfizer Access in event of Material Breach	  	28
		  	12.4	  	Pfizer Remedy for Breach.	  	28
			
	13.	  	Intellectual-Property License.	  	29
		  	13.1	  	License to Pfizer	  	29
			
	14.	  	Training of Pfizer Personnel in the Assay; Materials and Documentation transfer.	  	30
			
	15.	  	Records; Other Assay Limitation.	  	31
		  	15.1	  	Records; Audits.	  	31
		  	15.2	  	Other Assay Limitation	  	31
			
	16.	  	Term; Termination.	  	31
		  	16.1	  	Term	  	31
		  	16.2	  	Termination Upon Exercise of Continuation Remedy by Pfizer	  	31
		  	16.3	  	Termination at Will	  	31
		  	16.4	  	Monogram Termination Right	  	32
		  	16.5	  	Other Termination Rights	  	32
		  	16.6	  	Effect of Termination.	  	32
			
	17.	  	Representations and Warranties	  	33
		  	17.1	  	Corporate Representations and Warranties	  	33

  

 iv 

							
		  	17.2	  	Additional Representations and Warranties of Monogram	  	34
			
	18.	  	Indemnities	  	35
		  	18.1	  	Mutual Indemnification.	  	35
		  	18.2	  	Indemnification Procedures.	  	36
		  	18.3	  	Exclusive Remedy	  	37
		  	18.4	  	Dispute Resolution	  	37
			
	19.	  	Miscellaneous	  	37
		  	19.1	  	Insurance	  	37
		  	19.2	  	Non-Exclusivity	  	37
		  	19.3	  	Costs, Expenses	  	38
		  	19.4	  	No Finders’ Fees	  	38
		  	19.5	  	Amendment and Waivers	  	38
		  	19.6	  	Successors and Assigns.	  	38
		  	19.7	  	Governing Law	  	38
		  	19.8	  	Severability	  	39
		  	19.9	  	Entire Agreement	  	39
		  	19.10	  	Notices	  	39
		  	19.11	  	Titles and Headings	  	40
		  	19.12	  	Counterparts	  	40
		  	19.13	  	Facsimile Signatures	  	40
		  	19.14	  	Further Assurances	  	40
		  	19.15	  	Third Parties	  	40
		  	19.16	  	Force Majeure	  	40

  

 v 

 COLLABORATION AGREEMENT 
 THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of May 5, 2006
(“Effective Date”) between MONOGRAM BIOSCIENCES, INC., a Delaware corporation with its offices at 345 Oyster Point Boulevard, South San Francisco, California 94080
(“Monogram”), and PFIZER INC., a Delaware corporation with its offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). Monogram and Pfizer are referred to herein
individually as a “Party” or collectively as the “Parties.” 
 RECITALS 
 WHEREAS, Pfizer is engaged in the business of discovering, developing and commercializing pharmaceutical products, and is currently
developing maraviroc, a novel CCR5 antagonist for the treatment of HIV; 
 WHEREAS, Monogram has developed a proprietary
tropism assay for use in analyzing the HIV virus in patients, and is currently conducting such assays in connection with clinical trials of Pfizer pursuant to a Master Services Agreement (“Master Services Agreement”), dated as of
November 14, 2002; 
 WHEREAS, concurrently with the execution of this Agreement, the Parties are entering into a
Security Agreement (“Collaboration Security Agreement”), dated as of the date hereof, pursuant to which Monogram will grant to Pfizer a security interest in certain of its assets to secure the performance of Monogram’s
obligations hereunder; 
 WHEREAS, concurrently with the execution of this Agreement, the Parties are entering into a Note
Purchase Agreement (“Note Agreement”), dated as of the date hereof, pursuant to which Pfizer will purchase, subject to the terms and conditions set forth therein, for $25 million a convertible promissory note issued by Monogram (the
“Note”); and 
 WHEREAS, Pfizer and Monogram wish to enter into a non-exclusive agreement regarding the
supply of Monogram’s assay in the US Territory and the expansion of commercial availability of such assay into the countries of the Ex-US Territory (as defined below) where maraviroc may be Launched (as defined below). 
 NOW, THEREFORE, in consideration of the foregoing and the covenants and promises contained in this Agreement and the Note
Agreement, the Parties agree as follows: 
 1. DEFINITIONS 
 1.1 “Additional Facility” means a testing facility established for the sole purpose of performing the Assay in the western United States (i) that contains all physical assets required to
perform the Assay in substantially the same manner as it is performed at the Monogram Facility as of the Effective Date, (ii) in which Pfizer is entitled to exercise the license rights set forth in Section 13.1, and (iii) that
possesses all Regulatory Approvals to conduct such activity in such location. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 1.2 “Action” means any order, writ, injunction, judgment, fine, action, claim,
suit, arbitration, subpoena or proceeding by or before any court or grand jury, any Governmental Authority or arbitration tribunal. 
 1.3
“Affiliate” means, with respect to any Person, another Person that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person, where
“control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of a Person, whether through the ownership of voting securities, by contract, as trustee or executor or
otherwise. For the avoidance of doubt, neither Party shall be deemed to be an Affiliate of the other. 
 1.4
“Agreement” has the meaning assigned to it in the preamble. 
 1.5 “Anticipated Launch Date”
means the date that Pfizer in good faith has estimated that the Launch Date for the Pfizer Product will occur in a specific country. 
 1.6 “Applicable Reimbursement Amount” means the Medicare Allowable Amount or National Limitation Amount (as applicable) in effect at such time. 
 1.7 “Arrange for Delivery” means making arrangements with couriers, consolidation laboratories or reference laboratories for
pick-up of Samples from Third Parties and their delivery to the Monogram Facility. 
 1.8 “Assay” means
Monogram’s proprietary phenotypic Co-receptor tropism diagnostic assay, and improvements, enhancements, refinements and modifications thereon, but excluding second-generation assays. 
 1.9 “Business Day” means any day on which banks are required to be open both in the City of New York and San Francisco.

 1.10 “Change of Control” has the meaning assigned to it in the Note. 
 1.11 “CLIA” means the Clinical Laboratory Improvement Amendments of 1988, as it may be amended from time to time. 
 1.12 “CMS” means the United States Centers for Medicare and Medicaid Services (formerly known as the Health Care Financing
Administration). 
 1.13 “Code” or “Codes” means the Code on Interactions with Healthcare
Professionals promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA), the American Medical Association Guidelines on Gifts to Physicians, and the Office of the Inspector General’s Guidance, released in April 2003, as
any of the foregoing may be amended or replaced from time to time and any analogous codes and guidelines in countries and territories outside the United States. 
 1.14 “Collaboration Security Agreement” has the meaning assigned to it in the recitals. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 2 

 1.15 “Commercial Assay” means any Assay requested or ordered by any Third Party
to be performed by Monogram, but excluding Assays requested or ordered by Pfizer or any other Person for purposes of conducting or supporting clinical development work or human clinical trials. 
 1.16 “Commercially Reasonable Efforts” means, [*]. 
 1.17 “Consolidator Performance Standards” has the meaning assigned to it in Section 4.5(iii). 
 1.18 “Continuation Remedy” is defined in Section 12.4. 
 1.19
“Continuation Remedy Term” means the term that begins on the date when Pfizer exercises the Continuation Remedy and ends on December 31, 2016. 
 1.20 “Costs of Services” means, for a given period, the cost as defined herein for Assays performed in such period, which shall be equal [*]. 
 1.21 “Costs of Services Cap” means, for 2007, [*], and for each succeeding year, an amount equal to [*].

 1.22 “Costs of Services Estimate” has the meaning assigned to it in Section 3.5(b) 
 1.23 “Cost of Services True-Up Amount” has the meaning assigned to it in Section 3.5(b) 
 1.24 “Costs of Services Reconciliation” has the meaning assigned to it in Section 3.5(b) 
 1.25 “Coverage” means, as determined by Monogram using Commercially Reasonable Efforts, the existence of funds available for
payment to Monogram for a specific Commercial Assay from private insurance, HMO plans, Medicare, Medicaid, state insurance funds or other forms of medical care reimbursement, or self-insurance or individual agreements to pay Monogram in advance.

 1.26 “CPT” means the American Medical Association’s (“AMA”) “Current Procedural
Terminology” as published in the AMA’s CPT Process Manual, Fourth Edition and any such future editions.. 
 1.27
“Customer” means a physician, lab technician, nurse, social worker, patient advocate, patient support personnel and other health-care provider. 
 1.28 “Diligent Efforts” means [*]. 
 1.29 “DOJ” means the
Department of Justice. 
 1.30 “Effective Date” has the meaning assigned to it in the preamble. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 3 

 1.31 “Encumbrance” means any security interest, pledge, mortgage, lien (statutory
or other), charge, option to purchase, lease or otherwise acquire any interest or any claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement or any preference, priority or other security agreement (including any
conditional sale or other title retention agreement). 
 1.32 “Established Country” shall mean Argentina, Australia,
Belgium, Canada, France, Germany, Italy, Mexico, the Netherlands, Poland, South Africa, Spain, Sweden, Switzerland, the United Kingdom and the USA, and each other country in the Ex-US Territory that satisfies the Established Assay Criteria,
effective as of the first day of the calendar quarter following satisfaction of the Established Assay Criteria, and once such country satisfies the Established Assay Criteria, will remain an Established Country for the remainder of the Term.

 1.33 “Established Assay Criteria” shall mean, with respect to a country, (i) [*] Qualifying Samples or
Patient blood samples in connection with Pfizer clinical trials originated from such country over a [*] period, either in connection with a Pfizer clinical trial or a Commercial Assay, and (ii) during such [*], the ratio of Qualifying Samples
to the total number of Samples that originated from such country is at [*] 
 1.34 “Qualifying Samples” shall mean
Samples or Patient blood samples in connection with a Pfizer clinical trial (i) that were actually received at the Monogram Facility, and (ii) with respect to which Monogram performed Successful Tests. 
 1.35 “Ex-US Country” has the meaning assigned to it in Section 3.1. 
 1.36 “Ex-US Territory” means worldwide other than the US Territory. 
 1.37 “FDA” means the United States Food and Drug Administration, or any successor federal agency thereto. 
 1.38 “FTC” means the Federal Trade Commission. 
 1.39 “GAAP” means generally accepted accounting principles in the United States of America as in effect from time to time. 
 1.40 “Governmental Approval” means any and all consents, approvals, licenses, qualifications, designations, registrations or
authorizations of any national, supra-national (e.g., the European Commission or the Council of the European Union), regional, state or other Governmental Authority. 
 1.41 “Governmental Authority” means any court, agency, department or other instrumentality of any foreign, federal, state,
county, city or other political subdivision. 
 1.42 “IND” means an Investigational New Drug Application filed with
the FDA or the analogous application or filing filed with any analogous agency or Government Authority outside of the United States (including any supra-national agency such as in the European Union) necessary to commence human clinical trials in
such jurisdiction, and including all regulations at 21 CFR § 312 et seq. and analogous regulations outside of the United States. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 4 

 1.43 “Indemnified Party” has the meaning assigned to it in Section 18.1.

 1.44 “Indemnifying Party” has the meaning assigned to it in Section 18.1. 
 1.45 “Infrastructure Plan” has the meaning assigned to it in Section 5.2(a). 
 1.46 “ISC” has the meaning assigned to it in Section 5.2(a). 
 1.47 “JSC” has the meaning assigned to it in Section 4.1. 
 1.48 “Launch” means the first shipment of commercial quantities of the Pfizer Product to a Third Party for commercial sale.

 1.49 “Launch Date” means, with respect to a specific country, the first date when commercial quantities of the
Pfizer Product are shipped to a Third Party for commercial sale. 
 1.50 “Laws” means any statutes or other laws,
statutes, ordinances, rules, regulations, orders, Codes, judgments or other enforceable requirements of any Governmental Authority. 
 1.51 “Losses” has the meaning assigned to it in Section 18.1. 
 1.52 “Major Markets”
means Brazil, France, Germany, Italy, Spain, and the United Kingdom. 
 1.53 “Medicare Allowable Amount” means, prior to the
establishment of the National Limitation Amount, the amount of reimbursement paid by Northern California CMS for the Assay. 
 1.54
“Monogram” has the meaning assigned to it in the preamble. 
 1.55 “Monogram Confidential
Information” means all information about any Monogram Technology, and any other information regarding the business and operations of Monogram that is disclosed (whether orally or in writing) prior to or after the Effective Date by Monogram
to Pfizer or its Affiliates, to the extent that such information is not (i) as of the date of disclosure to Pfizer, known to Pfizer other than by virtue of a prior confidential disclosure to Pfizer by Monogram; (ii) disclosed in published
literature, or otherwise generally known to the public through no fault or omission of Pfizer; (iii) obtained from a Third Party free from any obligation of confidentiality to Monogram; or (iv) independently developed by Pfizer without
access or reference to the Monogram Confidential Information as shown by competent written proof. 
 1.56 “Monogram
Copyrights” means the registered copyrights identified on Annex B and any other copyrights that are owned, licensed (but only to the extent that further license rights may be granted by Monogram or a successor licensee in respect of such
licensed rights) or 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 5 

 otherwise controlled by Monogram and used in connection with the Assay following the Effective Date. At the request of
Pfizer, such request not to be made more than once per calendar quarter, Monogram will provide an update of Annex B. 
 1.57
“Monogram Facility” means Monogram’s Assay testing facility currently located at 345 Oyster Point Boulevard, South San Francisco, California and any successor location as may be designated by Monogram in its sole
discretion. 
 1.58 “Monogram Intellectual Property” means the Monogram Patent Rights, the Monogram Technology, the
Monogram Trademarks, and the Monogram Copyrights. 
 1.59 “Monogram Patent Rights” means the Patent Rights listed in
Annex C and all other Patent Rights owned, licensed (but only to the extent further license rights may be granted by Monogram or a successor licensee in respect of such licensed rights) or otherwise controlled by Monogram and that claim
Monogram Technology. At the request of Pfizer, such request not to be made more than once per calendar quarter, Monogram will provide an update of Annex C. 
 1.60 “Monogram Technology” means any Technology necessary or useful in the development, processing or commercialization of the Assay and that was or is owned, licensed (but only to the extent
that further license rights may be granted by Monogram or a successor licensee in respect of such licensed rights) or otherwise controlled by Monogram or any of its Affiliates, either alone or jointly with a Third Party, prior to, as of or after the
Effective Date. 
 1.61 “Monogram Trademarks” means the trademarks that are owned, licensed (but only to the extent
that further license rights may be granted by Monogram or a successor licensee in respect of such licensed rights) or otherwise controlled by Monogram and used in connection with the Assay following the Effective Date, other than the name
“Monogram”. 
 1.62 “National Limitation Amount” means the amount of reimbursement established by CMS for
the Assay pursuant to Section 1833(h)(4)(B) of the federal Social Security Act. 
 1.63 “NDA” means a New Drug
Application, filed with the FDA, as more fully defined in 21 C.F.R. §314.50 et. seq. 
 1.64 “Note” has
the meaning assigned to it in the recitals. 
 1.65 “Note Agreement” has the meaning assigned to it in the recitals.

 1.66 “Parties” has the meaning assigned to it in the preamble. 
 1.67 “Patent Rights” means all claims contained in patent applications and issued or granted patents, whether domestic or
foreign, including continuations, continuations-in-part, divisionals, provisionals and renewals, and letters of patent granted with respect to any of the foregoing, patents of addition, supplementary protection certificates, registration or
confirmation patents and all reissues, re-examination and extensions thereof and any patent restoration or extension period granted by a Governmental Authority, including compensation for patent term lost during the clinical trial or Regulatory
Approval process. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 6 

 1.68 “Patient” means any person in respect of whom a Commercial Assay has been
requested or ordered. 
 1.69 “Performance Standards” means the standards for Assay testing set forth in Annex
A. 
 1.70 “Person” means an individual, corporation, partnership, company, joint venture, unincorporated
organization, limited liability company or partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental Authority. 
 1.71 “Pfizer” has the meaning assigned to it in the preamble. 
 1.72 “Pfizer Agent” means any agent, consultant or contractor of Pfizer that is approved by Monogram, such approval not to be
unreasonably withheld. 
 1.73 “Pfizer Confidential Information” means all information about any Pfizer Technology,
and any other information regarding the business and operations of Pfizer, that is disclosed (whether orally or in writing) prior to or after the Effective Date by Pfizer to Monogram or its Affiliates, to the extent that such information is not
(i) as of the date of disclosure to Monogram, known to Monogram other than by virtue of a prior confidential disclosure to Monogram by Pfizer; (ii) disclosed in published literature, or otherwise generally known to the public through no
fault or omission of Monogram; (iii) obtained from a Third Party free from any obligation of confidentiality to Pfizer; or (iv) independently developed by Monogram without access or reference to the Pfizer Confidential Information as shown
by competent written proof. 
 1.74 “Pfizer Facility” means a testing facility established for the sole purpose of
performing the Assay (i) that contains all physical assets required to perform the Assay in substantially the same manner as it is performed at the Monogram Facility as of the Effective Date, (ii) in which Pfizer is entitled to utilize the
license rights set forth in Section 13.1, (iii) possesses all Regulatory Approvals to conduct such activity in such location and (iv) is located at a site owned, leased or controlled by Pfizer within the continental United States.

 1.75 “Pfizer Facility Term” shall mean the term that begins on the date when Pfizer starts to perform human
clinical trial Assays in the Pfizer Facility (if any) pursuant to the second sentence of Section 11.2(b) and ends upon the termination or expiration of this Agreement. 
 1.76 “Pfizer Product” means maraviroc, also known as UK-427,857, and described chemically
4,4-difluoro-N-{(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl} cyclohexanecarboxamide, as disclosed and specifically claimed in United States Patent No. 6,667,314, and any salts, esters,
prodrugs, metabolites, polymorphs and derivatives thereof, including any finished formulations of the foregoing. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 7 

 1.77 “Pfizer Technology” means any Technology necessary or useful in the
discovery, development, manufacture or commercialization of the Pfizer Product that is invented, discovered, owned, licensed, acquired or otherwise controlled by Pfizer or any of its Affiliates, either alone or jointly with any Third Party prior to
or after the Effective Date. 
 1.78 “Privacy Regulations” means the Privacy Regulations 45 C.F.R. Parts 160 and 164.

 1.79 “Reimbursement Approval” means, with respect to countries where Governmental Authorities authorize
reimbursement for, or approve or determine pricing for Commercial Assays for reimbursement or other compensation, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement
authorization or pricing approval or determination. 
 1.80 “Regulatory Approval” means any and all approvals,
authorizations, licenses, permits, accreditations and certifications of any national, supra-national (e.g., the European Commission), regional, state or local regulatory agency, department, bureau, commission, council or other
Governmental Authority that are necessary for a Party (or a Third Party acting on its behalf) in connection with pharmaceutical products, diagnostic services or to undertake an activity contemplated by this Agreement, including, in the case of the
performance of the Assay within the US Territory, all certifications under CLIA. 
 1.81 “Regulatory Authority” means
any Governmental Authority with responsibility for granting any Regulatory Approval, including the FDA in the United States and any regulatory authority of countries of the European Union and Japan, and, where applicable, any ethics committee or any
equivalent review board. 
 1.82 “Regulatory Filing” means any filings required by Regulatory Authorities relating to
Regulatory Approvals. 
 1.83 “Representatives” means, with respect to a Party, such Party’s Affiliates,
licensees, officers, directors, employees, consultants, contractors, sublicensees and agents. 
 1.84 “Sample” means a
Patient blood sample (i) for which a Customer has provided a complete test requisition form requesting a Commercial Assay (it being understood that Monogram shall use Commercially Reasonable Efforts to obtain any missing information) and
(ii) that satisfies the Sample Handling Guidelines. 
 1.85 “Sample Handling Guidelines” means Monogram’s
published guidelines as may be in effect from time to time, the current version of which is attached hereto as Annex D. 
 1.86
“Senior Executive” means, in the case of Pfizer, the worldwide commercial head of Infectious Diseases, and in the case of Monogram, William D. Young, Chairman and Chief Executive Officer, or any successor positions thereto which
include substantially the same responsibilities and authority. 
 1.87 “SOP” means standard operating procedures.

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 8 

 1.88 “Successful Test” means an Assay test that has yielded a reportable result
within forty (40) days following Monogram’s receipt of the associated Sample in the Monogram Facility. 
 1.89
“Tangible Material” means all tangible materials including vectors and cell lines, protocols, SOP’s and analytical software that relate to the use of the Monogram Patent Rights, the Monogram Technology or the Assay, each as
may be necessary to enable Pfizer to perform the Assay, including all improvements to such tangible materials, which may from time to time be incorporated into the Assay, as they are refined and improved. 
 1.90 “Technology” means all scientific and technical information, data, software and designs, including know-how, trade secrets
and technology related thereto, but excluding any Patent Rights. 
 1.91 “Term” has the meaning set forth in
Section 16.1. 
 1.92 “Third Party” means a Person other than (i) Pfizer, (ii) Monogram or
(iii) an Affiliate of either of them. 
 1.93 “Third Party Claim” has the meaning assigned to it in
Section 18.2. 
 1.94 “US Territory” means the United States of America, including Puerto Rico. 
 1.95 Construction. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:
(i) “include,” “includes” and “including” are not limiting; (ii) definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (iii) references to an
agreement or instrument mean such agreement or instrument as from time to time amended, modified or supplemented; (iv) references to a Person are also to its permitted successors and assigns; (v) references to an “Article,”
“Section,” “Exhibit” or “Schedule” refer to an Article or Section of, or any Exhibit or Schedule to, this Agreement unless otherwise indicated; (vi) the word “will” shall be construed to have the same
meaning and effect as the word “shall”; and (vii) the word “any” shall mean “any and all” unless otherwise indicated by context. In the event an ambiguity or a question of intent or interpretation arises, no
presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement. 
 2.
SUPPLY OF ASSAY IN THE US TERRITORY 
 2.1 US
Territory Supply. Subject to the provisions of this Section 2, Monogram agrees that it shall use Commercially Reasonable Efforts to make the Commercial Assay available for sale to Customers in the US Territory in such amounts as may be
ordered. As between Pfizer (and its Affiliates) and Monogram, Monogram will have the sole right and responsibility to sell and perform the Assay in the US Territory, except as provided in Articles 11 and 12. 
 2.2 Reimbursement Responsibility. Monogram will use Commercially Reasonable Efforts to obtain Coverage from payers in the US Territory for the
Commercial Assay at its own  
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 9 

 risk and expense promptly following Regulatory Approval of the Pfizer Product in the US Territory, which efforts shall
include attempts to obtain applicable CPT codes for the Commercial Assays. Pfizer shall have no obligation to seek to obtain Coverage from payers in the US Territory or to compensate Monogram with respect to Commercial Assays sold to Third Parties
in the US Territory, but will provide reasonable assistance if Monogram encounters difficulty in obtaining reimbursements with respect to payers to the extent the JSC determines such assistance is necessary, at Monogram’s expense. Reports
regarding Monogram’s reimbursement status and plans for the Commercial Assay in the US Territory will be provided to the JSC on a quarterly basis. 
 2.3 Fulfillment Standards for the US Territory. Monogram will use Commercially Reasonable Efforts to Arrange for Delivery of all Samples originating from Customers in the US Territory. Monogram shall be
required to perform the Commercial Assay with respect to Samples originating from Customers in the US Territory and received at the Monogram Facility in each calendar quarter based upon their Coverage as provided below:  
 (a) All such Samples in respect of Patients who have Coverage in an amount [*] of the Applicable Reimbursement Amount [*]; 
 (b) in the case of such Samples in respect of Patients who are not [*], but have Coverage in an amount [*] of the Applicable
Reimbursement Amount (such Samples, “[*],” and such Patients, “[*]”), a number of [*] in a given calendar quarter that are no fewer than the lesser of (i) [*] of all Samples in such
calendar quarter and (ii) the total number of [*] in such calendar quarter; provided that if in the calendar quarter that includes the first anniversary of Launch in the US Territory, the percentage of [*] of all
Samples in such calendar quarter, the percentage of [*] that Monogram will be required to perform thereafter will be increased for each subsequent calendar quarter to no fewer than [*] of all Samples in a given calendar
quarter and (y) the total number of [*] in such calendar quarter; provided, further, that such percentage shall be reviewed at the end of each successive calendar quarter, and will be reversed once the percentage of
[*] in a given calendar quarter falls below [*] of all Samples in such calendar quarter; and 
 (c) [*].

 For illustration purposes examples of the fulfillment standards for this Section 2.3 are attached as Annex E. 
 2.4 Supply of Other Assays. 
 (a)
Monogram’s Indigent Patient Program. To the extent Monogram in its sole discretion offers and performs HIV tests for indigent patients, it shall also offer and perform the Commercial Assay on a no less favorable basis on behalf of indigent
patients. 
 (b) Pfizer Marketing Programs. In addition to the Non-Covered Patients, Pfizer shall have the right to require that
Monogram perform the Commercial Assay to support its Launch activities/marketing programs within the US Territory at a per Assay cost to Pfizer equal to the Applicable Reimbursement Amount, up to a maximum of [*] Commercial Assays per

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 10 

 calendar year. Pfizer will inform the JSC of the method by which Pfizer intends to have the Commercial Assay distributed,
whether by vouchers, coupons or other means. Monogram will invoice Pfizer at the end of each calendar month for all Successful Tests performed under such programs, and Pfizer shall pay Monogram for such Commercial Assays in accordance with Article
6. 
 3. SUPPLY OF ASSAY IN THE EX-US TERRITORY

 3.1 Ex-US Supply. In any country in the Ex-US Territory in which Pfizer intends to Launch the Pfizer Product, Pfizer shall have
the right to require Monogram to make the Commercial Assay available for sale to Customers located in such country pursuant to this Section 3.1 (any such country where Pfizer exercises such right, an “Ex-US Country”);
provided that Pfizer first shall have obtained any Regulatory Approvals related to the sale of Commercial Assays in such country. As between Pfizer and Monogram, Monogram will have the sole right and responsibility to perform the Assay in the
Ex-US Territory, except as provided in Articles 11 and 12. Monogram shall use Commercially Reasonable Efforts to Arrange for Delivery of all Samples originating from Customers in each Ex-US Country (unless it has been relieved of its obligations to
implement the Infrastructure Plan for such Ex-US Country as provided in Article 5). Monogram shall perform the Commercial Assay with respect to any Samples originating from Customers in Ex-US Countries and received at the Monogram Facility.

 3.2 Reimbursement Responsibility. Pfizer shall be fully responsible for obtaining any reimbursement and pricing from payers,
including Reimbursement Approvals, at its own expense and risk, in any Ex-US Country. Monogram will reasonably cooperate with Pfizer and consolidation partners in obtaining any Reimbursement Approvals in such countries, at Pfizer’s expense.
Monogram will be fully subrogated to Pfizer with respect to the right to receive reimbursement or other payment from Third Parties for Commercial Assays performed in respect of Samples originating in the Ex-US Territory. In the event that a Third
Party makes a payment to Monogram in respect of a Commercial Assay performed in respect of a Sample originating in the Ex-US Territory, Monogram shall promptly remit such amount to Pfizer.  
 3.3 Regulatory Responsibility. With respect to any Ex-US Country for which Regulatory Approvals related to the sale of Commercial Assays are
applicable, either (i) if mutually agreed by both Parties, Monogram shall use commercially reasonable efforts to obtain any Regulatory Approvals related to the sale of Commercial Assays in such country, at Pfizer’s expense, or
(ii) otherwise Pfizer (or a Pfizer Agent) shall use commercially reasonable efforts to obtain such Regulatory Approvals itself at its own expense, but as Monogram’s agent or Representative, in which case Monogram shall provide Pfizer with
information reasonably requested and cooperate with Pfizer in connection with the applicable Regulatory Filings.  
 3.4 Sales and
Marketing Responsibility. Pfizer shall, at its own expense and risk, be fully responsible for sales and marketing of Commercial Assays in any Ex-US Country, including but not limited to the provision of medical education, marketing materials,
test requisition forms, Sample Handling Guidelines, advertisements, and training. Monogram will reasonably cooperate with Pfizer in providing sample marketing and training materials in English, at Pfizer’s expense.  
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 11 

 3.5 COMPENSATION. 
 (a) In consideration for making available for sale Commercial Assays to Customers in the Ex-US Territory, for Commercial Assays performed with respect to a Sample originating in an Ex-US Country, Pfizer shall
pay to Monogram an amount equal to [*], plus an amount equal to [*], plus, for each Successful Test, [*] for such Commercial Assays, plus, in the case of any Commercial Assays relating to Samples that originated from an Established Country in which
the Consolidator Performance Standards have been met for the previous calendar quarter, an additional incentive payment equal to [*]. The amounts paid pursuant to this Section 3.5 will be in addition to [*]. Monogram will invoice Pfizer at the
end of each month for all Commercial Assays performed with respect to Samples originating in any Ex-US Country, providing details related to such country. Pfizer shall pay Monogram for such Commercial Assays in accordance with Article 6. 

(b) The calculation of Costs of Services shall be determined based upon an estimate prior to the commencement of each quarter and a
reconciliation at the end of such quarter (or upon any earlier termination of the Agreement or end of the Term) as provided in this Section 3.5(b). 
 (i) No later than thirty (30) days prior to the beginning of each calendar quarter during the Term, beginning with the first quarter of 2007, Monogram shall deliver to Pfizer its reasonable and good faith
estimate of the Costs of Services for Commercial Assays for the following quarter of the Term, together with reasonable supporting documentation relating thereto (a “Costs of Services Estimate”). No later than the 45th day following the end of each calendar quarter during the Term, beginning with the first quarter of 2007, Monogram shall
deliver to Pfizer a reconciliation of the Costs of Services Estimate for the immediately preceding quarter to the actual Costs of Services incurred in respect of such quarter together with reasonable supporting documentation relating thereto (a
“Costs of Services Reconciliation”). 
 (ii) The calculation of the Costs of Services Reconciliation
by Monogram shall be subject to review by Pfizer and, if Pfizer disagrees with such calculation within fifteen (15) Business Days of submission by Monogram, the parties shall resolve such dispute through the dispute reconciliation procedures
set forth herein. The amount by which the Costs of Services Estimate exceeds or is less than the Costs of Services Reconciliation (as such amount is finally agreed by the parties or resolved through dispute resolution) in respect of a given quarter,
expressed as a positive or negative number, is the “Costs of Services True-Up Amount.” 
 (iii) If the
Costs of Services True-Up Amount is determined pursuant to clause (ii) to be a positive number, Monogram shall within thirty (30) days of such determination repay to Pfizer, the amount by which all payments made pursuant to
Section 3.5(a) in respect of the preceding quarter were overstated. Similarly, if the Costs of Services True-Up Amount is determined pursuant to the clause (ii) to be a negative number, Pfizer shall within thirty (30) days of such
determination pay to Monogram the amount by which the Costs of Services for the preceding quarter were understated. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 12 

 (iv) Any Costs of Services Estimate provided in respect of the second quarter of
2007 or any quarter thereafter shall be assumed to be revised to be consistent with the amount for Costs of Services reflected in the Costs of Services Reconciliation for the preceding quarter, effective upon the issuance thereof, absent
demonstrable changes in circumstance. For the avoidance of doubt, nothing in this Section 3.5(b) shall limit the Parties’ rights and obligations under Section 15.1. 
 4. GOVERNANCE STRUCTURE OF THE ASSAY COLLABORATION. 
 4.1 Joint Steering Committee. 
 (a)
A joint steering committee composed of three (3) employees from each of Pfizer and Monogram (the “JSC”) shall oversee all aspects of Commercial Assay supply, distribution, logistics, reimbursement and regulatory matters
related to this Agreement, including those matters specified in Section 4.5. Each of Pfizer and Monogram shall designate one of its representatives as a co-chair of the JSC. 
 (b) Initially, the JSC will consist of the following individuals: 
  

			
	Pfizer:	    	[*]
		    	(Co-chair)
		    	[*]
		
	Monogram:	    	[*] (Co-chair)
		    	[*]
		    	[*]

 (c) Each Party shall be entitled to change its representatives and/or designate a new
co-chair at any time on notice to the other Party. The co-chairs shall be jointly responsible for setting the agenda for each meeting, and each co-chair will be responsible for chairing alternating JSC meetings. From time to time, the JSC may
establish subcommittees or subordinate committees (that may or may not include members of the JSC itself) to oversee particular projects or activities, and such subcommittees or subordinate committees shall be constituted and shall operate as the
JSC agrees. At the end of the Term, the JSC shall be automatically disbanded without action by either Party. 
 4.2 Decision-Making
Authority. 
 (a) All decisions of the JSC made pursuant to this Agreement shall be made by unanimous approval of the members of
the JSC. In the event the JSC cannot resolve any matter properly referred to it, either Party may refer the matter to the Senior Executives for resolution. If after discussing the matter in good faith and attempting to find a mutually satisfactory
resolution to the issue, the Senior Executives fail to come to an agreement on the matter within fifteen (15) Business Days of the date on which the matter is referred to the Senior Executives, the final decision-making authority shall be
granted either to Pfizer or Monogram in accordance with Section 4.2(b) or 4.2(c), as applicable, and resolutions and final decisions reached through such provisions shall be binding on the Parties, subject in all cases to Section 4.2(d).

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 13 

 (b) Monogram will have final decision-making authority with respect to matters related to supply,
distribution, logistics, reimbursement, regulatory matters, sales and marketing to the extent related to the Commercial Assays in the US Territory. For clarification, Pfizer will have sole responsibility for the development, registration, labeling
or commercialization of the Pfizer Product. Pfizer shall have no responsibility to supply, promote, distribute, seek reimbursement for, or for regulatory matters related to, the Assay in the US Territory. 
 (c) Pfizer will have final decision-making authority with respect to matters related to distribution, logistics, reimbursement, regulatory
matters, sales and marketing related to Commercial Assays in each Ex-US Country. 
 (d) Decisions of the JSC or the Senior Executives
must be made in good faith and consistent with the provisions of this Agreement. For the avoidance of doubt, nothing in this Article 4 shall deprive a Party of its rights as otherwise provided under this Agreement. In addition, no decision made by a
Party’s Senior Executive under this Section 4.2 shall require the Party that does not have final decision-making authority to incur expenses in addition to those contemplated under this Agreement without reimbursement from the Party having
such final decision-making authority, or to engage in activities that are not commercially reasonable or that such Party in good faith believes are not in compliance with applicable Law. 
 4.3 Meetings. Following the Effective Date, the JSC shall hold meetings at such times and places as the JSC co-chairs determine (it being expected
that any in-person meetings will alternate between the appropriate United States offices of Pfizer and Monogram), but in no event shall such meetings be held less frequently than once every calendar quarter. The JSC may: 
 (a) conduct such meetings in person, by videoconference or by telephone conference; 
 (b) invite other personnel of the Party to attend meetings of the JSC as appropriate to the agenda for such meeting, after giving advance notice
to the other Party; 
 (c) act without a meeting if, prior to such action, a consent thereto is signed by the co-chairs of the JSC;
and 
 (d) by unanimous consent, amend or expand upon the foregoing procedures for its internal operation. 
 4.4 Minutes. At each meeting, the JSC shall elect a secretary who will prepare minutes promptly after each meeting, reporting in reasonable detail
the actions taken by the JSC during such meeting, issues requiring resolution, and resolutions of previously reported issues. Such minutes are to be reviewed and, if reasonably complete and accurate, signed by the JSC co-chairs. The secretary shall
revise such minutes as necessary to obtain such signatures. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 14 

 4.5 JSC Functions and Powers. The JSC shall manage the activities of the Parties as set forth in
this Section 4.5, unless otherwise mutually agreed in writing by the Parties. Notwithstanding anything to the contrary contained in this Agreement, the JSC shall not have right to amend this Agreement or make any decision or require either
Party to take any action that conflicts with the terms of this Agreement or that would impose, without reimbursement, additional financial and other obligations on either Party, unless mutually agreed to by the Parties. The JSC shall encourage and
facilitate the collaborative relationship and information exchange between the Parties in order to assist each Party in fulfilling its obligations hereunder, and shall in particular: 
 (i) monitor the progress of the Parties carrying out their responsibilities hereunder; 
 (ii) determine the physician education with respect to the Commercial Assay; 
 (iii) discuss and coordinate Pfizer’s planning and decision making process for initiating the Additional Facility or the
Pfizer Facility; 
 (iv) discuss and monitor access and reimbursement issues throughout the Territory; 
 (v) address regulatory matters and issues and coordinate contacts with Regulatory Authorities; 
 (vi) discuss the Monogram Trademarks; and 
 (vii) perform such other functions as appropriate to further the purposes of this Agreement as mutually determined by the Parties.

 With respect to the availability of Commercial Assays in countries in the Ex-US Territory pursuant to Section 3.1, the JSC shall
also: 
 (i) discuss, coordinate, approve and monitor plans regarding the availability of Commercial Assays;

 (ii) determine and approve the infrastructure required to support the availability of Commercial Assays, including
the associated budget; 
 (iii) determine whether to use couriers and/or consolidation laboratories in a country,
select such couriers and/or consolidation laboratories, approve contracts with such couriers and/or consolidation laboratories and establish Consolidator Performance Standards applicable to each Ex-US Country; and 
 (iv) approve all budgets, contracts and staffing requirements for the Ex-US Infrastructure Costs and Ex-US Operating Costs.

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 15 

 4.6 Independence. Subject to the terms of this Agreement, the activities and resources of each
Party shall be managed by such Party, acting independently and in its individual capacity. The relationship between Monogram and Pfizer is that of independent contractors and neither Party shall have the power to bind or obligate the other Party in
any manner, other than as is set forth in this Agreement. Monogram and Pfizer are not joint ventures, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting parties. 
 5. MONOGRAM’S EX-US INFRASTRUCTURE AND OPERATING COSTS.

 5.1 Ex-US Country Infrastructure. In each Ex-US Country, Monogram shall, to the extent approved by the JSC as described in
Section 5.2 below, use Diligent Efforts to establish and thereafter maintain an operational infrastructure of personnel, relationships and resources, it being understood that Monogram’s or its business partners’ personnel may be
requested to cover several such countries. The infrastructure established pursuant to this Section 5.1 will service each Ex-US Country(ies) for purposes of assisting with the selection of couriers and/or consolidation laboratory partners, and
management of Sample shipping to the Monogram Facility (including through the consolidation laboratories, as appropriate), and support Pfizer’s reimbursement and regulatory efforts subject to Section 3.3. All contracts (subject to the
approval of JSC) and employee relationships will be entered into by Monogram, and as between Monogram and Pfizer, Monogram will be solely obligated thereunder. 
 5.2 Monogram Infrastructure Roles and Responsibilities. 
 (a) Infrastructure Plan.

 (i) As provided in this Section 5.2, Monogram will use Diligent Efforts to create an infrastructure plan
outlining the functions described in Section 5.1 above to service each Ex-US Country (each such plan, an “Infrastructure Plan”). 
 (ii) The JSC will periodically meet to discuss Pfizer’s Launch plans for the Ex-US Territory and to inform Monogram of the Ex-US Countries which Monogram will be responsible for creating an Infrastructure
Plan for those countries in which Pfizer desires to Launch the Pfizer Product in the Ex-US Territory, and where Pfizer elects to have the Commercial Assay available for sale. The first such JSC meeting will occur within thirty (30) days
following the Effective Date, at which time the Parties will discuss the Launch plans and Pfizer will present the JSC with its Launch plans and a general description of its needs for services, whether it desires to consider consolidator laboratories
and request that the JSC assign responsibilities for creating an Infrastructure Plan to Monogram for the countries set forth opposite the year 2006 in Annex I. Thereafter, the JSC will meet at least semiannually to assign Monogram responsibilities
for creating additional Infrastructure Plans in additional Ex-US Countries. In no event shall Monogram be required to create more Infrastructure Plans per country/region in each calendar year than as set forth in Annex I. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 16 

 (iii) Monogram will have a budget for the purposes of creating Infrastructure
Plans equal to [*] in 2006, with which it may engage consultants and pay other out-of pocket expenses beginning on the Effective Date. The budget for subsequent calendar years will be established and approved by the JSC no later than
October 1 of the prior year. 
 (iv) At the first meeting of the JSC described above, the JSC shall form an
infrastructure sub-committee (“ISC”) consisting of representatives from both Parties. The ISC will meet frequently (either in person or otherwise) to monitor the activities of and consult with Monogram, and advise on the optimal
scope of services to be provided to service each Ex-US Country for which Monogram is creating the Infrastructure Plan. Monogram will use Diligent Efforts to present the Infrastructure Plan for each Ex-US Country to the JSC for review no later than
six (6) months after the JSC’s related request. 
 (v) The Infrastructure Plan will consist of an analysis of
the feasibility, benefits, issues, risks, optimal strategy for securing the services of Third Parties and estimated budget for the following: 
  

	 	A.	Consolidation laboratory approach (to the extent requested) 

  

	 	B.	Courier approach 

  

	 	C.	Combination of (A) and (B) (to the extent requested) 

 (b) Infrastructure Plan Approval Process. The JSC may, following review, either approve or reject elements of the Infrastructure Plans for each of the Ex-US Countries. To the extent the JSC rejects any or all elements of any of
Monogram’s proposed Infrastructure Plans, Monogram shall have no obligation under Section 3.1 with respect to Arranging for Delivery of Commercial Assays in such Ex-US Country, under Section 5.5, or to implement such Infrastructure
Plan or to maintain an infrastructure with respect to such Ex-US Country. 
 5.3 Infrastructure Plan Implementation Process.

 (a) To the extent the JSC approves the elements of an Infrastructure Plan, Monogram shall use Diligent Efforts to implement the
Infrastructure Plan to service the related Ex-US Country within the budget presented by Monogram, provided the JSC shall approve any final contracts. Monogram shall use Diligent Efforts to make such Infrastructure Plan operational at the
later of one (1) month prior to the Anticipated Launch Date or six (6) months following approval of such Infrastructure Plan by the JSC. 
 (b) Monogram will use Diligent Efforts to implement the Infrastructure Plan in coordination with the ISC. For each Ex-US Country where Monogram has implemented an infrastructure, Monogram shall present an annual budget for the
country-specific infrastructure and courier or consolidation lab contract expenses/pricing to the JSC no later than on October 1 preceding the budget year. If Monogram believes that providing the approved services will exceed the budget for the
applicable Ex-US Country by more than [*], Monogram shall promptly 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 17 

 inform the JSC. If the actual expenses are more than [*] above the budgeted amounts, Pfizer may assume for
the following year the responsibility for the applicable Ex-US Country’s infrastructure, provided that (i) such assumption will not relieve Pfizer of (a) its obligations under Section 5.7 with respect to the payment of
Ex-US Infrastructure Costs and Ex-US Operating Costs incurred prior to the time at which Pfizer assumes responsibility for such country or (b) its remaining obligations under Section 5.7 with respect to the payment of Ex-US
Infrastructure Costs and Ex-US Operating Costs that are not specific to such country, (ii) Pfizer will reimburse Monogram for any [*], and (iii) Monogram will cooperate in transitioning its operations to Pfizer, and use
Diligent Efforts to assign any applicable Third-Party contracts to Pfizer, in each case for such Ex-US Country. 
 5.4 Front End
Transfers. In the event the JSC determines that a front-end transfer of the Commercial Assay to a consolidation laboratory for performing part of the Commercial Assay process is the only means of obtaining a required Regulatory Approval in a
specific Ex-US Country in the Ex-US Territory, Monogram will incorporate in its Infrastructure Plans the elements of such front-end transfer. 
 5.5 Logistic Responsibility in Ex-US Countries. With respect to Samples originating in any Ex-US Country, to the extent Monogram has established the infrastructure to service such relevant country, Monogram shall use commercially
reasonable efforts to implement and manage logistics (including distribution and shipping from the site of Patient Sample blood draw, i.e., physician’s office or local laboratory) to support the performance of the Commercial Assay with
respect to any such Sample received at the Monogram Facility. Without limiting the foregoing, Monogram will use commercially reasonable efforts to provide logistical support in such countries in English, manage the consolidation partners, couriers
and Sample distribution channels that route Samples from the point of the blood draw site to such channels and then to the Monogram Facility. In order to facilitate Monogram’s management of distribution and shipping of Samples, Pfizer shall
provide communication and feedback to health-care providers regarding the shipping requirements. Monogram will have sole responsibility for providing test results in local languages, as appropriate. 
 5.6 Employees; Contractors. Except as specifically provided herein, Monogram shall have exclusive control over its employees and independent
contractors. Nothing in this Agreement shall be construed to conclude that any agents or employees of Monogram are agents or employees of Pfizer or subject to Pfizer’s direction and control. Monogram shall have sole authority over the terms and
conditions of its agents’ and employees’ employment, and shall select, engage, and discharge its agents and employees at its discretion. Monogram will be solely responsible for compensating its agents and employees whom it assigns to
perform services under this Agreement, including paying salaries and expenses, providing benefits, deducting any applicable United States or foreign payroll taxes, FICA, unemployment, workers compensation, medical or other insurance contributions
and making any other payments required by applicable Law to be made on behalf of such employees. 
 5.7 Ex-US Infrastructure Costs and
Operating Costs. Pfizer will reimburse Monogram for [*] incurred by Monogram in connection with the performance of its obligations under this Article 5. The [*] will include, among other things, specifically
[*] (“Ex-US Infrastructure Costs”), as well as [*] (“Ex-US Operating Costs”). 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 18 

 5.8 Payments. Monogram will invoice Pfizer at the end of each month for all expenses incurred in
connection with the performance of its obligations under this Article 5, and Pfizer shall reimburse Monogram for such expenses in accordance with Article 6. The invoice will itemize each category of expenses identified in this Article 5, as well as
other expenditures related to activities approved by the JSC or the ISC. The amounts under Section 5.7 above in any quarter shall be reduced pro-rata on a country-by-country basis using the volume and number of Commercial Assays performed in an
Ex-US Country in proportion to the total volume and number of assays performed by Monogram for Samples originating in such country, if Monogram utilizes the infrastructure developed in such country to conduct business other than the activities
contemplated by this Agreement. 
 6. INVOICING AND PAYMENTS 
 6.1 Invoicing. Monogram shall invoice Pfizer at the end of each month in respect of the amounts to be paid to Monogram with respect to such month
pursuant to Sections 2.3(c), 2.4(b), 3.5, 5.8, 11.2 and 11.3. Pfizer shall make all payments in respect thereof by wire transfer in accordance with the wire instructions set forth in Section 6.2 below, within thirty (30) days after
Pfizer’s receipt of each invoice. Pfizer may request, and Monogram shall provide to Pfizer upon such request, any reasonable additional supporting documentation relating to such invoices. 
 6.2 Payment Method. All payments due under this Agreement from Pfizer to Monogram shall be made at payor’s election, by electronic transfer
in immediately available funds via a bank wire transfer to such bank account(s) as Monogram shall designate in writing at least five (5) Business Days before the payment is due. All payments hereunder shall be made in US dollars. Conversion of
compensation under Section 3.3 or expenses as recorded in local currencies to U.S. dollars for the purpose of calculating the payments made under this Agreement will be performed in a manner consistent with Monogram’s normal practices used
to prepare its audited financial reports; provided that such practices use a widely accepted source of published exchange rates. 
 6.3 Taxes. 
 (a) It is understood and agreed between the parties that any payments made to Monogram under this
Agreement shall be exclusive of any tariffs, duties or taxes imposed or levied by any Governmental Authority, and all such tariffs, duties or taxes, with the exception of income taxes payable by Monogram, are the sole responsibility of Pfizer. If
such tariffs, duties or taxes are paid or required to be paid by Monogram, an equivalent amount shall be added to the amount payable by Pfizer under this Agreement. 
 (b) Each Party agrees to cooperate and produce on a timely basis any tax forms or reports, including an IRS Form W-8BEN, reasonably requested by the other Parties in connection with any payment made by Pfizer
to Monogram under this Agreement. Each Party further agrees to provide reasonable cooperation to any of the other Parties, at such other Party’s expense, in connection with any official or unofficial tax audit or contest relating to payments
made by Pfizer to Monogram under this Agreement. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 19 

 (c) In the event any of the payments made by Pfizer pursuant to this Agreement become subject to
withholding taxes under the Laws of any jurisdiction, Pfizer shall increase its payment to Monogram such that Monogram receives the full amount it would have received absent such withholding. Monogram will provide Pfizer with reasonable assistance
to enable Pfizer to recover such taxes as permitted by Law. Monogram agrees to reasonably co-operate with Pfizer in any valid tax exemption or reimbursement procedure permitted by any applicable double taxation treaty and to co-operate in complying
with any procedural formalities (including the submission of applicable documentation) necessary (i) to enable Pfizer to make payments owed hereunder without a tax withholding, or with any reduced tax withholding which applies under the terms
of the applicable double taxation treaty, or (ii) for Pfizer to obtain a refund of any taxes withheld. 
 6.4 Interest. All
payments under this agreement shall bear interest from the date due until the date paid at a rate equal to the thirty (30) day U.S. dollar LIBOR rate effective for the date that payment was due, as reported by The Wall Street Journal,
plus 1%, computed on an actual/360 basis. 
 6.5 Advances. Notwithstanding anything herein to the contrary, in the event Pfizer
elects to exercise its right, pursuant to the last proviso of Section 6(a) of the Note, to treat a portion of the outstanding amount of the Note as an advance against amounts owed by Pfizer hereunder, Pfizer shall thereafter be relieved of its
obligations to make payments hereunder until the full amount of such advance is exhausted. 
 7. PFIZER AND
CUSTOMER EDUCATION. 
 7.1 Pfizer Education. Monogram shall educate Pfizer personnel, as appropriate,
on a periodic basis, on the specifications, benefits and limitations of the Assay, as well as on shipping and handling of Samples. 
 7.2
Customer Education. Appropriately trained Pfizer representatives and Monogram representatives, where deployed (it being understood that neither Party shall have any obligation to deploy any such personnel), shall each educate the Customers on
the Commercial Assay and the procedures for processing thereof. Pfizer sales representatives will be solely responsible for detailing the Pfizer Product. Monogram shall make no claim that it has any right or interest in the Pfizer Product, and will
not promote the Pfizer Product unless expressly permitted by Pfizer. Pfizer shall make no claim that it has any right or interest in the Commercial Assay, except as provided in Section 11.2(b) and Section 12.4, and Pfizer shall not, and
shall not be required to, make any statements with respect to the Commercial Assay, or, except as expressly set forth in this Agreement, provide instruction or give advice on reimbursement for the Commercial Assay, except as mutually agreed by the
Parties and approved by the JSC. Notwithstanding the foregoing, Pfizer may insert any content approved by Monogram pertaining to the Commercial Assay into its own educational or promotional materials, provided Pfizer shall not change such content.
Pfizer may request copies of any Monogram content pertaining to the Commercial Assay for Launch in the US Territory, which Monogram shall provide within three (3) months of such request. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 20 

 7.3 Materials; Call Center. Monogram will coordinate development of electronic versions of
training and educational materials relating to the Commercial Assay for Pfizer personnel and Customers in English. Monogram will be responsible for establishing a call center to handle inquiries related to the Commercial Assay. For the Ex-US
Territory, prior to Launch in an Ex-US Country, Pfizer will notify Monogram if additional call center resources will be required for such country or if inquiries for such country will be routed to Pfizer personnel. If additional call center
resources are required, Monogram will obtain such resources to handle the calls from such country, at Pfizer’s expense pursuant to Section 5.7. 
 8. REGULATORY AFFAIRS; COMPLIANCE WITH LAW. 
 8.1 Regulatory Filings and Approvals. 
 (a) In the US Territory, Monogram shall be responsible for preparing and
submitting all Regulatory Filings and seeking and maintaining all Regulatory Approvals for the Commercial Assay, including preparing all reports necessary as part of a Regulatory Filing or Regulatory Approval. Subject to the proviso to
Section 10.2, Pfizer shall provide all information and cooperation reasonably requested by Monogram in connection with any Regulatory Filing or Regulatory Approval or correspondence with any Regulatory Authority. 
 (b) In the Ex-US Territory, Pfizer shall be responsible for preparing and submitting all Regulatory Filings and seeking and maintaining all
Regulatory Approvals for the Commercial Assay, including preparing all reports necessary as part of a Regulatory Filing or Regulatory Approval. Subject to the proviso to Section 10.2, Monogram shall provide all information and cooperation
reasonably requested by Pfizer in connection with any Regulatory Filing or Regulatory Approval or correspondence with any Regulatory Authority. 
 8.2 Compliance with Law. 
 (a) Each of the Parties shall comply with all Laws applicable to its conduct relating to
this Agreement, including federal, foreign, and state fraud and abuse and self-referral laws and all laws pertaining to access to and use, maintenance, and transmission of HIV-related and other confidential patient information, laboratory services
billing, marketing and sales, and specimen packaging and transport. Each Party represents and warrants that with respect to all protected health information (as that term is defined in the Privacy Regulations) if and to the extent such Party may
have access to the protected health information, it is either a covered entity (and not a business associate of the other party) or otherwise permitted to have access to the protected health information under the Privacy Regulations and that it
shall protect the privacy, integrity, security, confidentiality and availability of the protected health information disclosed to, used by, or exchanged by the parties by implementing and maintaining privacy and security policies, procedures, and
practices, and administrative, physical and technological safeguards and security mechanisms that reasonably and adequately protect the confidentiality, integrity and availability of the protected health information created, received, maintained or
transmitted under this 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 21 

 Agreement, all as required by, and set forth more specifically in, the Privacy Regulations and the Security Regulations,
as each may be amended from time to time. In the event HIPAA or the Privacy Regulations or Security Regulations require any addition to or modification of this Agreement, the parties shall use commercially reasonable efforts to agree upon such
additions or modifications in a timely manner. 
 (b) The Parties agree that neither will take any action in the performance of its
obligations hereunder to improperly influence in any manner the results of any Commercial Assay, it being of paramount importance to both Parties that accurate test information be provided to all Customers and Patients for whom the Commercial Assay
is performed. 
 8.3 Licensure. The Monogram Facility is and shall remain duly licensed or certified clinical laboratories under CLIA.
Monogram shall use commercially reasonable efforts to obtain any other Regulatory Approvals required with respect to the Assay, or the Monogram Facility, including any which the FDA determines are required. Pfizer will use commercially reasonable
efforts to assist Monogram in obtaining such Regulatory Approvals. Monogram shall provide documentation of such license or certification upon Pfizer’s request. All Commercial Assays performed by Monogram shall be in accordance with applicable
state and federal testing requirements for clinical reference laboratories. Monogram shall maintain, and hereby certifies its and its employees are in possession of, all existing necessary Regulatory Approvals to perform the Commercial Assays in the
US Territory and to undertake all other obligations of Monogram hereunder and shall maintain all such Regulatory Approvals during the Term.  
 8.4 Excluded Provider. Monogram represents and warrants that it is not an Excluded Provider. For purposes of this Section 8.4, the term “Excluded Provider” means a person or entity that either (i) has been
convicted of a crime related to health care, or (ii) is currently listed by a federal agency as debarred, excluded or otherwise ineligible for participation in federally funded programs (including federally-funded health care programs such as
Medicare and Medicaid). Monogram shall notify Pfizer within five (5) days after Monogram receives notice that it is an Excluded Provider. 
 9. OWNERSHIP OF MATERIALS AND INTELLECTUAL PROPERTY 
 9.1 Except as specifically provided in this Agreement, no royalty or other payment will be due to Monogram, its officers, employees, agents or permitted sub-contractors from Pfizer with respect to
Monogram’s performance of its obligations under this Agreement. 
 9.2 For the avoidance of doubt, except as expressly provided
in this Agreement, neither Pfizer nor its Affiliates shall have any right, title or interest in or to any Monogram Technology, Monogram Intellectual Property or Monogram Confidential Information, including the testing methods, practices, or
procedures or in the test apparatus or equipment, or any improvements thereto, developed by Monogram during the conduct of its business, whether used in the performance of this Agreement or otherwise, and Pfizer hereby acknowledges that it shall not
acquire any right in respect thereof and that all such rights and good will are and shall remain vested in Monogram, except as contemplated in Articles 11 and 12, and the Collaboration Security Agreement. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 22 

 9.3 For the avoidance of doubt, nothing in this Agreement shall give Monogram any right, title or
interest in or to any of Pfizer’s compounds or methods of compound synthesis, including the Pfizer Product, Pfizer Technology, Patent Rights owned, licensed or controlled by Pfizer or Pfizer Confidential Information. 
 9.4 For purposes of further clarification, nothing in this Agreement shall give Pfizer or its Affiliates any rights in relation to any of
Monogram’s nucleic acid based vectors or its assay technology, except as contemplated in Articles 11 and 12, and the Collaboration Security Agreement. 
 10. CONFIDENTIALITY 
 10.1 Treatment of Confidential Information. The Parties agree that during the
Term, and for a period equal to the earlier of ten (10) years of the Effective Date and five (5) years after the end of the Term, each Party will, and will cause its Affiliates, (i) to maintain in confidence all Monogram Confidential
Information or Pfizer Confidential Information, as the case may be, to the same extent such Party maintains its own proprietary information of similar kind and value and (ii) not to use such Monogram Confidential Information or Pfizer
Confidential Information, as the case may be, for any purpose except those expressly permitted by this Agreement. Pfizer and its Affiliates agree not to disclose any Monogram Confidential Information to any Third Parties under any circumstance
without the prior consent of Monogram. Except as permitted by Sections 10.2 or 10.3 below, Monogram and its Affiliates agree not to disclose any Pfizer Confidential Information to any Third Parties under any circumstance without the prior consent of
Pfizer. If any Change of Control of Monogram occurs, Monogram shall notify Pfizer promptly after execution of the agreement providing for a transaction that, if consummated, would result in a Change of Control, and, at Pfizer’s request,
Monogram will, and will cause any Person that becomes an Affiliate of Monogram upon consummation of such Change of Control to, impose restrictions on access to the Pfizer Confidential Information including, without limitation, establishing
firewalls, as reasonably requested by Pfizer. 
 10.2 Authorized Disclosure. Pfizer and Monogram each agree that any disclosure
(i) by Pfizer or any of its Affiliates of Monogram Confidential Information, or (ii) by Monogram or any of its Affiliates of Pfizer Confidential Information, in each case to any of their respective officers, employees or agents shall be
made only if and to the extent reasonably necessary to carry out its rights and obligations under this Agreement and shall be limited to the maximum extent possible consistent with such rights and obligations. Monogram and Pfizer each represent that
all of their directors, officers, employees and agents who shall have access to Pfizer Technology, Monogram Technology, Pfizer Confidential Information or Monogram Confidential Information are bound by an agreement to maintain such information in
confidence. Notwithstanding the foregoing, (x) Pfizer may disclose any Monogram Confidential Information to (I) Governmental Authorities (a) to the extent reasonably necessary to obtain or maintain INDs or Regulatory Approvals for the
Pfizer Product, (b) to the extent reasonably necessary to respond to inquiries, requests or investigations, and (c) to the extent reasonably necessary to obtain Regulatory Approval and pricing and reimbursement of the sale of the
Commercial Assay in any Ex-US Country, including any Reimbursement Approval, (II) Pfizer Agents or other business consultants, attorneys, accountants or professional service providers, except for 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 23 

 medical, scientific or technical consultants in the area of HIV or antiretroviral resistance testing, and (III) to the
extent necessary in order to enforce Pfizer’s rights under this Agreement or the Note Agreement, (y) Monogram may disclose any Pfizer Confidential Information (I) to Governmental Authorities in order to respond to inquiries, requests
or investigations, (II) to attorneys, accountants or professional service providers (III) to outside consultants, suppliers or subcontractors in connection with the Assay, (IV) to the extent necessary in order to enforce Monogram’s rights under
this Agreement; and (z) Pfizer and Monogram may disclose any Monogram Confidential Information and Pfizer Confidential Information, respectively, when required to be disclosed under Law or in connection with a legal proceeding; provided
that, in each case enumerated in clauses (x), (y), and (z) of this Section 10.2, the disclosing Party shall obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own proprietary information
of similar kind and value. 
 10.3 Publicity. The press release announcing the signing of the transaction contemplated by this
Agreement is attached as Annex F hereto and will be promptly disseminated following signing. Pfizer shall have the sole right to make public announcements regarding the Pfizer Products in the Territory. Monogram shall have the sole right to
make public announcements regarding the capabilities of the Assay, the availability of the Assay, the existence and general terms of this Agreement and the Note Agreement, and progress of Monogram’s business with regard to the Assay, which are
consistent with the press release attached hereto as Annex F. Without Pfizer’s consent, Monogram shall not be permitted to make any public announcement concerning the reliability of the Commercial Assay that implies that Pfizer endorses
or makes representations to the public concerning the accuracy and reliability of the Assay, except for announcements that acknowledge the relative contractual responsibilities of the Parties under this Agreement. Other than such announcements,
neither party, without the prior approval of the other party, shall originate any publicity, news release or public announcement, written or oral, whether to the public press, stockholders or otherwise, relating to this Agreement, the subject matter
to which it relates, performance under it or any of its terms, to any amendment hereto or performance hereunder (herein referred to as an “Announcement”), except for such an Announcement which (x) is required by Law, applicable
stock exchange regulation or legal (including but not limited to judicial, arbitral and administrative) proceedings to be made or (y) is contained in a Party’s filings with the Unites States Securities and Exchange Commission. Other than
public announcements described in the second and third sentences of this Section 10.3 and Announcements described in clauses (x) and (y) of this Section 10.3, a Party will give the other Party at least ten (10) days’
advance notice of the text of any proposed Announcement so that the other party will have an opportunity to comment upon the Announcement. For an Announcement required by clause (x) of this Section 10.3, each party will endeavor to give
the other Party reasonable notice, which presumptively shall be ten (10) days notice, unless circumstances require that the Announcement be released sooner. 
 10.4 Data Ownership; Publications. Pfizer shall be the sole owner of any data or other information related to the Pfizer Product, Pfizer Product data or tropism data generated in a Pfizer clinical trial or
otherwise controlled by Pfizer, and neither Monogram nor its Affiliates will have any right to publish or present any information related to the Pfizer Product, Pfizer Product data or Pfizer tropism data without the consent of Pfizer. Monogram shall
be the sole 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 24 

 owner of any data or other information related to tropism data generated by Monogram independently of Pfizer’s human
clinical trials or otherwise controlled by Monogram, and neither Pfizer nor its Affiliates will have any right to publish or present any information related to such tropism data without the consent of Monogram. 
 10.5 Agreement Filing. To the extent, if any, that a Party concludes that it is required under applicable Laws to file or register this Agreement
or a notification thereof with any Governmental Authority, including the United States Securities and Exchange Commission, the FTC or the DOJ, such Party may do so; provided that such Party shall provide the other Party with a written copy of
all proposed filings, registrations or notifications within such time frame as to allow for a reasonably sufficient time for review and comment by the other Party prior to the submission of such proposed filing, registration or notification. The
other Party shall cooperate with such filing, registration or notification and shall execute all documents reasonably required in connection therewith. To the extent permitted by applicable Law, the Parties will request confidential treatment of
sensitive provisions of this Agreement. The Parties shall promptly inform each other as to the activities or inquiries of any such Governmental Authority relating to this Agreement and shall cooperate to respond to any request for further
information therefrom. 
 11. ADDITIONAL OR PFIZER TESTING FACILITY

 11.1 Establishment of Additional Testing Facility. The Parties acknowledge that Pfizer may desire during the Term to establish
an Additional Facility or a Pfizer Facility (but not both) which, in either case, as between Pfizer and Monogram, shall be owned or leased by Pfizer. Pfizer shall have the right, exercisable in its sole discretion at any time by notice to Monogram,
to require Monogram to undertake any or all of the activities specified below associated with the establishment of an Additional Facility or Pfizer Facility, it being acknowledged that (i) the Parties will use Diligent Efforts to ensure that
any Additional Facility shall be operational, including obtaining any applicable Regulatory Approvals within fifteen (15) months of the date of such notice and (ii) Monogram shall not be authorized to and shall not enter into any
contractual obligation with respect to the Additional Facility or Pfizer Facility to be developed pursuant to this Article 11 without the advance approval of Pfizer. At the request of Pfizer, Monogram shall use Diligent Efforts to: 
 (a) Identify modifications and improvements in the physical location selected for the Additional Facility or the Pfizer Facility that are required
to perform the Commercial Assay; 
 (b) Identify all equipment and third party services (including insurance coverage and courier and
other logistical support services) required to perform the Commercial Assay at the Additional Facility or the Pfizer Facility; 
 (c)
With respect to an Additional Facility, negotiate with vendors of the equipment and services identified in the preceding clause; 
 (d) Establish protocols for the performance of the Commercial Assay at such Additional Facility; 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 25 

 (e) Identify Regulatory Approvals needed to perform the Assay in the Additional Facility or the
Pfizer Facility, and use Commercially Reasonable Efforts to obtain Regulatory Approval of the Additional Facility under CLIA; 
 (f)
In the case of the Additional Facility, identify and retain the personnel who shall be employed at such facility; 
 (g) Create,
develop and implement a comprehensive training program for personnel who will be employed at either the Additional Facility or the Pfizer Facility; and 
 (h) Provide such other services as may be reasonably necessary to commence operations at such Additional Facility and are reasonably requested by Pfizer to be provided. 
 11.2 Operation of Additional Testing Facility. 
 (a) In the case of the Additional Facility, Monogram shall operate the Additional Facility and performing the Assay and shall employ and be responsible for all salary, benefits and other obligations to the
persons required to carry out these functions, shall maintain insurance coverage in respect of such operations and comply with all applicable Laws. Monogram shall retain any and all payments received from Customers or otherwise in respect of Assays
performed at the Additional Facility. Monogram shall operate the Additional Facility in consultation with the JSC and in accordance with all requirements hereunder that would apply to its operation of the Monogram Facility and the performance of the
Commercial Assay in the Monogram Facility. Upon not less than two weeks notice to Monogram, Pfizer or any Pfizer Agent shall have the right to appoint a reasonable number of personnel to observe the activities at the Additional Facility no more
frequently that once per calendar quarter, and pursuant to the provisions of Section 14.1, Monogram shall train any such persons in all aspects of the Assay and its performance. Notwithstanding anything herein to the contrary, in the event
Pfizer exercises its Continuation Remedy, Pfizer shall have the right to assume control of the operations of the Additional Facility. 
 (b) In the case of a Pfizer Facility, Pfizer or Pfizer Agent shall operate such facility and shall employ all individuals who are operating such facility and performing the Assay at such location, it being agreed that such personnel
shall be trained by Monogram as part of the establishment of such facility as specified in Section 11.1. For so long as Pfizer has not exercised its Continuation Remedy, Pfizer agrees that the only activity or business it shall perform at such
facility shall be the performance of no more than [*] of the Assays necessary to support Pfizer’s human clinical trials, and it shall pay Monogram a royalty of [*] for each such Assay it performs. Following the exercise of
Pfizer’s Continuation Remedy, the royalty for Pfizer’s human clinical trial requirements shall be governed by Section 12.4(c). 
 11.3 Reimbursement. Pfizer shall reimburse Monogram for [*] incurred in providing the assistance contemplated by Section 11.1 and the services specified in Section 11.2(a), provided that such
reimbursement for services specified in Section 11.2(a) shall not be required in any calendar year in which Monogram performs more than [*] Commercial Assays. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 26 

 11.4 Abandonment. Notwithstanding anything in this Article 11 to the contrary, Pfizer shall have
the right in its sole discretion to abandon the establishment of an Additional Facility or the Pfizer Facility; provided, however, that (i) such abandonment shall not relieve Pfizer of its obligations under Section 11.3, and
(ii) after commencement of Monogram services pursuant to Section 11.2(a), Pfizer shall first provide Monogram with not less than six (6) months advance notice. 
 11.5 Monogram Option. At the end of the Term or upon any abandonment of an Additional Facility during the Term, Monogram shall have an option to
acquire any of the equipment and other assets owned by Pfizer that are part of the Additional Facility or the Pfizer Facility for an amount equal to the depreciated book value of such equipment and other assets (as evidenced by reasonable supporting
documentation provided by Pfizer), and (ii) assume all obligations under any real property lease or other contract related solely to the Additional Facility; provided, however, if this agreement terminates pursuant to Sections 16.2 and
16.5, Monogram shall forfeit such option, and if Pfizer terminates this Agreement during the continuance of a material breach (other than a material breach resulting in a termination under Section 16.2), Monogram’s right to purchase such
equipment and other assets shall be at the actual cost incurred by Pfizer and not the depreciated book value. 
 11.6 Alternative
Arrangements. The Parties recognize that it may be mutually beneficial and may wish in good faith to propose, discuss and review potential alternative arrangements with a view of providing Pfizer with other methods by which it can obtain
operational and other benefits similar to those provided under Sections 11.1 through 11.5 above. For clarification, the Parties agree that the failure to engage in discussions or to reach mutual agreement on the subject matter of this
Section 11.6 shall not constitute a breach of this Agreement by either Party, nor shall it affect the rights and obligations of the Parties under Sections 11.1 to 11.5 above. 
 12. PERFORMANCE STANDARDS; CERTAIN BREACH REMEDIES 
 12.1 Forecasting. 
 (a) Beginning one year prior to the first Anticipated Launch Date of the
Pfizer Product, and each at the beginning of each [*] thereafter, Pfizer shall provide Monogram with a non-binding forecast of the [*] demand for the Commercial Assay within the Territory for the following [*] (which forecasts will include
activity/marketing demand and any “special programs” to be conducted by Pfizer) so that Monogram may make plans to meet the demand for the Commercial Assay (the “Rolling Forecast”). 
 (b) Pfizer’s Rolling Forecast for the Commercial Assay shall be considered “Locked” for the [*] for which a Rolling Forecast is
provided. For purposes of illustration, the dates of the “Locked” Rolling Forecast are provided below: 
  

			
	 Date on or before which Rolling Forecast is provided
	 	 Pfizer’s Forecast is “Locked” for the aggregate of the three
months

	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 27 

 (c) In the event that in any [*] the actual demand for the Assay [*], Monogram shall
not be required to meet the Performance Standards for such [*], and Monogram shall not be held in material breach for non-compliance with such standards, provided, however, it shall use Diligent Efforts to complete the Assays as quickly as
practicable under the circumstances. 
 (d) All Rolling Forecasts will be non-binding and shall not imply any obligation on the part
of Pfizer to purchase itself or warrant the purchase of Assays by itself or any Third Party. 
 12.2 Performance Standards. Monogram
shall perform its obligations in respect of Commercial Assays with respect to Samples originating in the Established Countries in accordance with the Performance Standards (other than the Consolidator Performance Standards), measured collectively on
a quarterly basis. 
 12.3 Pfizer Access in event of Material Breach. In the event of any material breach of Sections 2.1, 2.2, 2.3,
3.1 and 12.2 of this Agreement, upon notice by Pfizer and subject to compliance with reasonable restrictions established by Monogram, Monogram shall permit Pfizer reasonable access to the Monogram Facility and its executives in order to observe or
discuss the activities at the Monogram Facility and to ascertain the cause of such material breach and a possible solution. 
 12.4
Pfizer Remedy for Breach. 
 (a) (i) Upon any material breach of Sections 2.1, 2.2, 2.3, 3.1 or 12.2 that is not cured within
ninety (90) days of a notice of such breach from Pfizer, or (ii) immediately upon the repudiation or rejection of Monogram’s obligations hereunder, Pfizer shall have the right, exercisable upon notice to Monogram, at any time
(a) such material breach is continuing or (b) Monogram has not thereafter acknowledged its obligations hereunder, respectively, but no later than one year following the relevant cure period, to commence performance of Assays for its own
human clinical trials and for the performance of the Commercial Assay, either itself and/or through a Third Party contractor, licensee, or sublicensee, including without limitation at the Additional Facility or the Pfizer Facility
(“Continuation Remedy”). Pfizer’s right to exercise its Continuation Remedy shall be in addition to any right of termination under Article 16 and any other remedies it may have at law or in equity. The Parties agree that a
material breach of Sections 2.1, 2.3, 3.1 or 12.2 will not arise to the extent failure to perform is caused by (a) consolidation laboratory performance, (b) any failure to complete a front-end transfer of the Assay, so long as Monogram
utilizes Commercially Reasonable Efforts to effect such transfer, and/or (c) an FDA exercise of jurisdiction over the Monogram Facility and/or the Assay, so long as Monogram utilizes Commercially Reasonable Efforts to comply with such FDA
requirements. 
 (b) For the purposes of exercising the Continuation Remedy at the Additional Facility or the Pfizer Facility, and
performing the Assay for clinical trials at the Pfizer Facility pursuant to Section 11.2(b), Monogram is hereby granting to Pfizer the following present rights and interests, (i) the non-exclusive license described in Article 13,
(ii) a security interest as set forth 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 28 

 in the Collaboration Security Agreement, and (iii) the right to use the Tangible Materials as described in
Section 14.2. In addition, for such purposes, Monogram is hereby granting to Pfizer the right for Pfizer personnel to be trained at the Monogram’s facility as described in Article 14. 
 (c) If following exercise of the Continuation Remedy, Pfizer performs the Assay, either directly (whether at the Additional Facility, the Pfizer
Facility or otherwise) or through the use of a Third Party, Pfizer shall pay Monogram a royalty of [*]. 
 (d) Monogram
shall use Commercially Reasonable Efforts to ensure that any license it obtains from a Third Party after the Effective Date with respect to Monogram Intellectual Property expressly permits Monogram to sublicense such license to a Third Party, and
expressly permits sublicensees to assume Monogram’s license rights upon an event that would otherwise result in termination of the license, or loss of such license rights. For clarification, in no event shall Monogram be obligated to obtain
such sublicensing rights if it would be required to pay additional consideration therefor (whether in the form of upfront payments or increased royalty rates). Monogram hereby acknowledges that in entering into its licensing arrangements with Third
Parties, it shall not obligate itself to pay higher royalties or other amounts for Third-Party intellectual property used in the Ex-US Territory relative to such intellectual property used in the US Territory. 
 (e) Monogram agrees that it will use Commercially Reasonable Efforts to obtain licenses to all Third Party intellectual property which Monogram
deems in its reasonable judgment to be necessary to make, use/perform, sell, and import the Commercial Assay. Monogram agrees that it will provide Pfizer with complete copies of any such licenses it obtains. 
 13. INTELLECTUAL-PROPERTY LICENSE. 
 13.1 License to Pfizer. (a) Subject to the terms of this Agreement and Section 13.1(b) below, Monogram hereby grants to Pfizer: 
 (i) a non-exclusive, worldwide, license, with the right to sublicense (to the extent permitted), to use the Monogram Technology,
the Monogram Copyrights, and the Monogram Confidential Information to make, have made, use/perform, sell or import the Assay (as it may exist as of the time these licensed rights are first exercised) in the Territory; 
 (ii) a non-exclusive, worldwide, license, with the right to sublicense (to the extent permitted), under the Monogram Patent Rights
to make, have made, use/perform, sell or import the Assay (as it may exist as of the time these licensed rights are first exercised) in the Territory; and 
 (iii) a non-exclusive, worldwide, license, with the right to sublicense (to the extent permitted), to use the Monogram Trademarks on or in connection with the Assay (as it may exist as of the time these
licensed rights are first exercised) in the Territory. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 29 

 (b) Notwithstanding anything in the contrary herein, Pfizer shall exercise or otherwise exploit
the licensed rights that are being granted on the Effective Date only (i) to exercise its rights as permitted under and pursuant to Section 11.2(b) and in that event only during the Pfizer Facility Term and (ii) to exercise its rights
as permitted under and pursuant to Sections 12.4(a) and 12.4(c) and in that event only during the Continuation Remedy Term. 
 (c) All
rights and licenses granted under or pursuant to this Agreement by Monogram are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined
under Article 101 of the U.S. Bankruptcy Code. The parties agree that Pfizer, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, or equivalent
legislation in any other jurisdiction. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Monogram under the U.S. Bankruptcy Code, Pfizer shall be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and any Tangible Material, if not already in their possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its request
therefor, unless Monogram elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Monogram upon request therefor by Pfizer.

 14. TRAINING OF PFIZER PERSONNEL IN THE ASSAY;
MATERIALS AND DOCUMENTATION TRANSFER. 
 14.1 Commencing thirty
(30) days after the filing of an NDA with respect to Pfizer Product, Pfizer shall have the right to have two (2) employees trained at the Monogram Facility in all aspects of performing the Assay at least annually, it being understood that
Pfizer may request that Monogram train different employees every year; provided, if there are modifications to the Assay performance, Monogram shall train Pfizer’s employees at the Monogram Facility upon Pfizer’s reasonable request
at the Monogram Facility; provided, further that during any time following satisfaction of one or more of the conditions set forth in Section 12.4(a)(i), (ii) or (iii), Pfizer shall be able to have such personnel trained and
present at the Monogram Facility on demand. 
 14.2 Monogram agrees to transfer the Tangible Material to Pfizer within 30 days of
execution of this Agreement, to be held by Pfizer for use solely for the purposes of exercising its rights under Sections 11.2(b), and upon exercise of the Continuation Remedy. Monogram also agrees to provide detailed storage instructions to enable
the safe keeping of Tangible Material. Monogram agrees to transfer to Pfizer all improvements to the Tangible Material which may from time to time be incorporated in to the Assays, as soon as reasonably practical following development by Monogram.

 14.3 In order for Pfizer to exercise its Continuation Remedy, Pfizer shall be free to make and reproduce such Tangible Materials
following the exercise of its Continuation Remedy to the extent necessary to perform Assays as permitted pursuant to Section 12.4 above and ensure the continued integrity/function of such Tangible Material. Monogram shall train a reasonable
number of Pfizer personnel with respect to the Tangible Materials for clinical use, including reproducing the Tangible Material to perform the Commercial Assay. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 30 

 14.4 Pfizer agrees that it will comply with all applicable governmental regulatory and statutory
requirements regarding use of the Tangible Materials. For the avoidance of doubt, Pfizer will make no use of the Tangible Material except as provided in Sections, 11.2(b) or 14.2 and until Pfizer has exercised its Continuation Remedy. 
 15. RECORDS; OTHER ASSAY LIMITATION. 
 15.1 Records; Audits. 
 (a)
Monogram shall, and shall cause its Affiliates and sublicensees to, provide to Pfizer the reports identified in Annex G, and keep accurate books and records related thereto. Monogram shall permit Pfizer, by independent qualified public
accountants employed by Pfizer and reasonably acceptable to Monogram, to examine such books and records at any reasonable time following the rendering of any corresponding reports, accountings and payments provided by Monogram hereunder. Such
accountants may be required by Monogram to enter into a reasonably acceptable confidentiality agreement, and in no event shall such accountants disclose to Pfizer any information other than such as relates to the accuracy of reports and payments
made or due hereunder. The opinion of such accountants regarding such reports, accountings and payments shall be binding on the Parties, other than in the case of manifest error. Pfizer shall bear the cost of any such examination; provided
that if such examination shows an overpayment by Pfizer of more than [*]% for the applicable period (for purposes of such calculation, differences, if any, between Costs of Services Estimates and Costs of Services Reconciliations delivered in
accordance with Section 3.5(b) shall be disregarded), then Monogram shall promptly reimburse Pfizer for all costs incurred in connection with such examination. Monogram shall promptly re-pay to Pfizer any amounts of any overpayments of amounts
revealed by an examination (including interest payable in accordance with Section 6.4), and Pfizer shall promptly pay to Monogram any amounts of any underpayments of amounts revealed by an examination (without any interest). 
 (b) Upon Pfizer’s reasonable request, Pfizer shall have the right to conduct an quality-assurance audit in accordance with Pfizer’s
quality-assurance policies then in effect. Pfizer shall be permitted to conduct such audit no more frequently than once every [*]. 
 15.2
Other Assay Limitation. During the Term, Monogram agrees that it shall not enter into any agreement or other arrangement with Third Parties providing that other HIV assays will be given priority ahead of the Commercial Assay. 
 16. TERM; TERMINATION. 
 16.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated as provided herein, shall continue until December 31, 2009, provided that Pfizer shall have the right to extend this
Agreement on up to five (5) successive occasions for additional terms of one-year each, such right to be exercised by providing notice to Monogram no later than six (6) months prior to the then applicable termination date
(“Term”). 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 31 

 16.2 Termination Upon Exercise of Continuation Remedy by Pfizer. This Agreement shall
automatically terminate upon the exercise by Pfizer of the Continuation Remedy. 
 16.3 Termination at Will. (a) After the
Effective Date, Pfizer may terminate this Agreement in whole or in part with respect to any country, at any time in its sole discretion, upon ninety (90) days’ advance notice to Monogram, with such termination becoming effective at the end
of such ninety (90)-day period. 
 (b) Monogram may terminate this Agreement in whole in the event Pfizer terminates this Agreement
with respect to all Ex-US countries pursuant to clause (a) of this Section. 
 16.4 Monogram Termination Right. If Monogram
believes that Pfizer is in material breach of this Agreement, Monogram may deliver notice of such material breach to Pfizer, such notice to describe in detail the nature of such breach. For purposes of this Section 16.4, a material breach shall
include a material inaccuracy in any representation or warranty contained herein. Pfizer shall have sixty (60) days from its receipt of such notice to cure such material breach. Any such termination shall become effective at the end of such
sixty (60)-day period unless Pfizer has cured any such breach prior to the expiration of such sixty (60)-day period. 
 16.5 Other
Termination Rights. If a Party is generally unable to meet its debts when due, or makes a general assignment for the benefit of its creditors, or there shall have been appointed a receiver, trustee or other custodian for such Party for all or
substantially all of its assets, or any case or proceeding shall have been commenced or other action taken by or against such Party in bankruptcy or seeking the reorganization, liquidation, dissolution or winding-up of such Party or any other relief
under any bankruptcy, insolvency, reorganization or other similar act or law, and any such event shall have continued for sixty (60) days undismissed, unstayed, unbonded and undischarged, the other Party may, upon notice to the first Party,
terminate this Agreement, such termination to be effective upon the first Party’s receipt of such notice. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 32 

 16.6 Effect of Termination. 
 (a) Survival. All covenants and agreements herein, including licenses and sublicenses granted hereunder shall terminate upon termination of this
Agreement; provided (A) that the following provisions shall survive any expiration or termination of this Agreement: Articles 1 (Definitions), 10 (Confidentiality), 18 (Indemnities), 19 (Miscellaneous), 9 (Ownership of Materials and
Intellectual Property), and this Section 16.6 (Effect of Termination), together with any sections or defined terms referred to in such provisions, surviving provisions necessary to give them effect, and (B) upon Pfizer’s exercise of
the Continuation Remedy, the following provisions shall survive in addition to the Articles and Section identified in the preceding subclause (A): Article 13 (Intellectual-Property Matters), and Sections 12.4(a), 12.4(b), 12.4(c), 14.2, 14.3 and
14.4, together with any sections or defined terms referred to in such provisions, surviving provisions necessary to give them effect. 
 (b) In the event Pfizer elects not to renew this Agreement pursuant to Section 16.1 or this Agreement is terminated pursuant to Sections 16.3(a), 16.4 or 16.5, Monogram shall advise Pfizer within ninety (90)-days of such notice
or election or termination whether it intends to dismantle the Infrastructure with respect to any Ex-US Country. In the event Monogram elects to dismantle such Infrastructure, provided Monogram takes commercially reasonable steps to minimize further
expenses, and Monogram actually terminates and winds-down contracts and terminates the employment of persons related thereto, Pfizer will reimburse Monogram for its out-of-pocket expenses incurred in connection with such termination and wind-down,
provided (i) Pfizer shall not be obligated to reimburse Monogram for any expenses associated with Monogram’s termination and wind-down that, if Pfizer terminates this Agreement due to Monogram’s material breach or exercise of
the Continuation Remedy and (ii) to the extent permissible by their terms, all agreements with couriers and consolidation laboratories will be assigned to Pfizer, if Pfizer exercises the Continuation Remedy. 
 (c) Any termination or expiration of this Agreement shall not relieve the Parties of any liability that accrued (including any liability that
accrued as of result of a breach) hereunder prior to such termination or expiration. In addition, any termination or expiration of this Agreement shall not preclude any Party from pursuing all rights and remedies it may have hereunder or under the
governing law as defined in Section 19.7 below (including specific performance and injunctive relief). The remedies provided herein are not exclusive of other remedies available to a Party under the governing Law as defined in Section 19.7
below. 
 17. REPRESENTATIONS AND WARRANTIES 
 17.1 Corporate Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Effective Date: 
 (a) such Party is a company duly organized, validly existing and, to the extent such concept is known in the respective jurisdiction, in good
standing under the Laws of its state of incorporation, and such Party has the full corporate power and authority to own and operate its properties and assets and to conduct its business as presently conducted by it. Such Party has all necessary
corporate power and authority to enter into this Agreement and perform its obligations hereunder and to carry out the transactions contemplated hereby; 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 33 

 (b) such Party is duly qualified to do business in its state of incorporation and is, to the
extent such concept is known in the respective jurisdiction, in good standing in each jurisdiction in which the character or location of its properties and assets owned or operated by it or the nature of the business conducted by it makes such
qualification necessary; 
 (c) all corporate action has been taken on the part of such Party’s directors and shareholders
necessary for the authorization, execution, delivery of, and the performance of all obligations of such Party under this Agreement. This Agreement, when executed and delivered by such Party, and assuming the due execution by the other Parties, will
constitute valid and legally binding obligations of such Party enforceable against such entity in accordance with its terms; 
 (d) no
Governmental Approval, or consent, approval or waiver of any other Person, is required to be made or obtained by such Party in connection with the execution and delivery of, and performance of its respective obligations under this Agreement and the
consummation of the transactions contemplated hereby; and 
 (e) neither the execution, delivery and performance of this Agreement by
such Party nor the performance by such Party of its obligations hereunder nor the consummation by such Party of the transactions contemplated hereby will result in (i) a material violation of or a conflict with any provision of its
organizational documents, (ii) a material breach or violation of, or a default under (with or without notice or lapse of time or both) any term or provision of, or any right of termination, cancellation, modification or acceleration arising
under any contract or by which any of their respective properties or assets are bound, (iii) a material violation by such Party of any Law or order, or (iv) the imposition of any encumbrance on the business, properties or assets of such
Party. 
 17.2 Additional Representations and Warranties of Monogram. Monogram further represents and warrants to Pfizer as follows,
as of the Effective Date: 
 (a) Monogram owns sufficient rights to Monogram Intellectual Property to perform its obligations under
this Agreement with respect to the US Territory and to grant Pfizer the license set forth in Article 13. Monogram has not transferred ownership of, or granted any exclusive license of, or exclusive right to use, or authorized the retention of any
exclusive rights to use, any Monogram Intellectual Property with respect to any other Person (except as provided herein). 
 (b)
Annex H hereto contains a list of all licensed third-party intellectual property licensed to Monogram for use in connection with the Assay. All such licensed intellectual property is licensed from a party other than Monogram pursuant to a
contract disclosed in Annex H. The Monogram Intellectual Property, together with the third-party intellectual property identified in Annex H, constitutes all intellectual property owned, licensed to or controlled by Monogram or any of
its Affiliates that is necessary or useful in the development, manufacture or use, performance, sale or importation of the Assay or that claims any Technology relating thereto. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 34 

 (c) To the knowledge of Monogram, except as set forth in the SEC Documents (as defined in the Note
Agreement), neither the Monogram Intellectual Property nor any activities of Monogram is the subject of a notice or claim regarding any infringement of any such rights. 
 (d) Neither this Agreement nor the transactions contemplated hereby shall result in (i) Monogram’s granting to any third party any right with respect to any Monogram Intellectual Property or, as the
case may be, any licensed third-party intellectual property, and (ii) Monogram being bound by, or subject to, any non-compete or other restriction on the use of the Monogram Intellectual Property or, as the case may be, any licensed third-party
intellectual property. Monogram has disclosed to Pfizer all material correspondence and contact information between it and the United States Food and Drug Administration or any other similar foreign regulatory authority regarding the Assay.

 (e) Monogram has disclosed to Pfizer all material information in Monogram’s possession related to the performance and
reliability of the Assay, and Monogram’s capabilities to perform the Assay. To the knowledge of Monogram, after due inquiry, all information provided by Monogram to Pfizer related to the performance, reliability, capabilities and US Territory
reimbursement for the Commercial Assay is true and correct in all material respects. 
 (f) Monogram is not a Party to any agreement
or other arrangement providing that other HIV assays will be given priority ahead of the Commercial Assay. 
 18. INDEMNITIES

 18.1 Mutual Indemnification. 
 (a) Each Party (each, an “Indemnifying Party”) hereby agrees to indemnify and hold the other Party and its Representatives (each, an “Indemnified Party”) harmless from and
against any and all Third Party claims, liabilities, obligations, losses, fines, costs, royalties, proceedings, or damages (whether absolute, accrued, conditional or otherwise), including out-of-pocket expenses and reasonable attorneys’ and
accountants’ fees incurred in the investigation or defense of any of the same (collectively, “Losses”), resulting from or arising out of or in connection with any breach of any representation, warranty, covenant or agreement
contained in this Agreement by the Indemnifying Party. 
 (b) Monogram hereby agrees to indemnify and hold Pfizer and its
Representatives harmless from and against any Losses resulting from or arising out of or in connection with any accident, illness or personal injury, including death, or property damage to the extent caused or allegedly caused by, or to the extent
related to, the Commercial Assay, except to the extent it arises from the breach of this Agreement or the negligence or willful misconduct of Pfizer. 
 (c) Pfizer hereby agrees to indemnify and hold Monogram and its Representatives harmless from and against any Losses resulting from or arising out of or in connection with any 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 35 

 accident, illness or personal injury, including death, or property damage to the extent caused or allegedly caused by, or
to the extent related to, the Pfizer Product, except to the extent it arises from the breach of this Agreement or the negligence or willful misconduct of Monogram. 
 18.2 Indemnification Procedures. 
 (a) Within ninety (90) days following receipt by the
Indemnified Party of notice of any pending or threatened Action, claim or demand by a Third Party (any such Action, claim or demand, a “Third Party Claim”) which could give rise to a claim for Losses under Section 18.1, the
Indemnified Party shall give notice thereof to the Indemnifying Party indicating the nature of such claim and the basis therefor (set forth in as complete and accurate a manner as practicable); provided, however, that failure to give
such notice shall not affect the indemnification provided hereunder, except to the extent the Indemnifying Party is materially and adversely prejudiced as a result of such failure. 
 (b) The Indemnifying Party shall have the right, at its option, to assume the defense of, at its own expense and by its own counsel reasonably
satisfactory to the Indemnified Party, any such matter involving the asserted liability of the Indemnified Party as to which the Indemnifying Party shall have acknowledged in writing to the Indemnified Party its obligation to fully indemnify the
Indemnified Party. If any Indemnifying Party shall, in accordance with the preceding sentence, undertake to compromise or defend any such asserted liability, it shall promptly notify the Indemnified Party of its intention to do so, and the
Indemnified Party shall agree to cooperate with the Indemnifying Party and its counsel in the compromise of, or defense against, any such asserted liability; provided, however, that the Indemnifying Party shall not settle any such
asserted liability without the prior written consent of the Indemnified Party; provided, further, however, that the immediately preceding proviso shall not apply in the case of any settlement which releases the Indemnified Party
completely in connection with such matter and which provides relief consisting solely of money damages borne by the Indemnifying Party. The Indemnified Party shall have the right to employ separate counsel and to participate in the defense of such
action or proceeding. 
 (c) The Indemnifying Party shall bear the reasonable fees, costs and expenses of one such separate counsel
for the Indemnified Party in each jurisdiction and shall pay such fees, costs and expenses at least quarterly, if, but only if, (x) the defendants in, or targets of, any such action or proceeding include both an Indemnified Party and the
Indemnifying Party, and such Indemnified Party shall have reasonably concluded that there may be legal defenses available to it or to other Indemnified Parties which are different from or additional to those available to the Indemnifying Party (in
which case the Indemnifying Party shall not have the right to direct the defense of such action or proceeding); (y) the Indemnifying Party shall not have employed counsel reasonably satisfactory to such Indemnified Party to represent such
Indemnified Party within a reasonable time after notice of the institution of such action or proceeding; or (z) the Indemnifying Party shall authorize such Indemnified Party to employ separate counsel at the Indemnifying Party’s expense.
In addition, the Indemnifying Party shall be liable for the reasonable fees and expenses of one counsel employed by the Indemnified Party for any period during which the Indemnifying Party has not assumed the defense thereof. The Indemnified Party
and its counsel shall cooperate with the Indemnifying Party and its counsel and shall not 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 36 

 assert any position in any proceeding inconsistent with that asserted by the Indemnifying Party; provided,
however, that the foregoing shall not prevent the Indemnified Party from taking the position that it is entitled to indemnification hereunder. All reasonable out-of-pocket costs and expenses incurred in connection with an Indemnified
Party’s cooperation shall be borne by the Indemnifying Party. The Indemnified Party shall have the right at its own expense to participate in the defense of such asserted liability. 
 18.3 Exclusive Remedy. Without limiting any right or remedy either Party may have hereunder or in law or equity in respect of any breach of this
Agreement that does not involve a Third Party Claim, and except for fraud, intentional misrepresentation, or gross negligence by any Party, the foregoing indemnification provisions are the sole and exclusive remedy for any claim for monetary relief
arising from Losses arising as a result of a breach of this Agreement. 
 18.4 Dispute Resolution. Resolution of all disputes arising
out of or related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, without regard to
conflicts of law rules that would provide for application of the law of a jurisdiction outside New York. Any such controversy or claim shall be resolved by the United States District Court for the Southern District of New York, a New York state
court sitting in New York, New York, the United States District Court for the District of Delaware, or a Delaware state court sitting in Wilmington, Delaware (collectively, the “Courts”). Each Party (a) irrevocably submits to
the exclusive jurisdiction in the Courts, for purposes of any action, suit or other proceeding relating to or arising out of this Agreement, and (b) agrees not to raise any objection at any time to the laying or maintaining of the venue of any
such action, suit or proceeding in any of the Courts, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action,
suit or other proceeding, that such Court does not have any jurisdiction over such Party. Monogram hereby irrevocably designates, appoints and empowers Corporation Service Company, located at 2711 Centerville Road, Suite 400, Wilmington, DE 19808,
as its true and lawful agent and attorney in fact in its name, place and stead to receive and accept on its behalf service of process in any action, suit or proceeding in the Courts of New York with respect to matters as to which it has submitted to
jurisdiction as set forth in the immediately preceding sentence. 
 19. MISCELLANEOUS 
 19.1 Insurance. Monogram agrees to procure and maintain in full force and effect during the Term valid and collectible insurance policies in
connection with its activities as contemplated hereby. Upon Pfizer’s request, Monogram shall provide Pfizer with a certificate of coverage or other written evidence reasonably satisfactory to Pfizer of such insurance coverage. 
 19.2 Non-Exclusivity. This Agreement shall be non-exclusive, and for clarification, does not prohibit either Party (whether alone or with Third
Parties) from researching, developing or performing any assay (including the Assay) used in the treatment or diagnosis of HIV. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 37 

 19.3 Costs, Expenses. Other than as provided herein, each Party shall pay its own costs, fees and
out-of-pocket expenses in connection with the preparation, execution and delivery of this Agreement and documents contemplated herein. 
 19.4 No Finders’ Fees. Each Party represents that it neither is nor will be obligated for any finders’, broker’s, financial advisors’ or other intermediaries’ fee or commission in connection with this
Agreement. 
 19.5 Amendment and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the consent of Pfizer and Monogram. No delay or failure to require performance of any provision of this Agreement shall constitute a
waiver of that provision as to that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the
waiver of any performance other than the actual performance specifically waived. 
 19.6 Successors and Assigns. 
 (a) Except as otherwise provided in this Agreement, the rights and obligations of the Parties will be binding upon and inure to the benefit of
their respective successors. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned, in whole or in part, by any Party without the prior consent of the other Party; provided that Pfizer may assign
this Agreement or any of its rights hereunder to any of its Affiliates without Monogram’s consent so long as Pfizer continues to be bound by all of its obligations under this Agreement. Any assignment or purported assignment of this Agreement
in breach of any provision hereof shall be null and void. 
 (b) Notwithstanding anything in this Agreement to the contrary, if an
assignment by one Party of its rights or obligations under this Agreement leads to the imposition of any value-added taxes or withholding tax liability on the other Party resulting from the performance of the Parties obligations under this Agreement
that would not have been imposed in the absence of such assignment or in an increase in such liability above the liability that would have been imposed in the absence of such assignment, the assigning Party shall indemnify and hold harmless the
non-assigning Party (or its assignee) from any such additional or increased tax liability (except to the extent that the non-assigning Party can reclaim it, provided that the assigning Party reimburses the non-assigning Party for any
reasonable out of pocket costs incurred in the reclaim). In the event of any such assignment, the assigning Party shall, or shall cause its assignee to, gross up any payments it makes to the non-assigning Party to the extent necessary so that the
net payment received by the non-assigning Party after such additional or increased tax liability equals the amount due under this Agreement. 
 19.7 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the State of New York without giving effect to its principles or rules of conflict of laws to the extent such principles or rules
would require or permit the application of the laws of another jurisdiction. 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 38 

 19.8 Severability. If any term or other provision of this Agreement is invalid, illegal or
incapable of being enforced by applicable Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is
not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 
 19.9 Entire Agreement. This Agreement and the Amendment to the Master Services Agreement, including all schedules, annexes and exhibits hereto and
thereto constitute the entire agreement and understanding of the Parties with respect to the subject matter of this Agreement, and supersede any and all prior understandings and agreements, whether oral or written, between or among the Parties with
respect to the specific subject matter hereof. 
 19.10 Notices. Any notices, approvals, or consents required or permitted to be given
under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if (i) mailed by first class certified or registered mail, postage prepaid,
internationally recognized overnight courier, (ii) personally delivered, or (iii) sent via facsimile. Unless otherwise specified in writing, the mailing addresses and fax numbers of the Parties shall be as described below: 
  

			
	For Monogram:	  	Monogram Biosciences Inc.
		  	345 Oyster Point Boulevard
		  	South San Francisco, California 94080
		
		  	Attention: Chief Executive Officer
		  	Facsimile No: +1 650-635-1111
		
	with a copy to:	  	Attention: General Counsel
		  	Facsimile No.: +1 650-635-1111
		
	For Pfizer:	  	Pfizer Inc.
		  	235 East 42nd Street
		  	New York, New York 10017
		
		  	Attention: President, Pfizer Human Health
		  	Facsimile No.: +1 212-808-8652
		
	with a copy to:	  	Attention: Vice Chairman, Executive Vice President and
		  	                  General Counsel
		  	Facsimile No.: +1 212-808-8924

 Notices hereunder shall be deemed to be effective (x) upon receipt if personally delivered or faxed,
(y) on the tenth (10th) Business Day following the date of mailing if sent by first class 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 39 

 certified or registered mail, and (z) on the second (2nd) Business Day following the date of transmission or
delivery to the overnight courier if sent by overnight courier. A Party may change its address or fax number listed above by sending notice to the other Parties in accordance with this Section 19.10. 
 19.11 Titles and Headings. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in
interpreting or construing this Agreement. 
 19.12 Counterparts. This Agreement may be executed in two or more counterparts, each of
which when so executed and delivered will be deemed an original of the Party or Parties executing the same, and all of which together shall constitute one and the same agreement. 
 19.13 Facsimile Signatures. This Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be
deemed to have the same effect as if the original signature had been delivered to the other Party. 
 19.14 Further Assurances. At any
time or from time to time after the Effective Date, the Parties agree to cooperate with each other, and at the request of any other Party, to execute and deliver any further instruments or documents and to take all such further action as the other
Party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the Parties hereunder. No Party shall be permitted hereunder to take any action for the
purpose of circumventing the provisions and purposes of this Agreement and the transactions contemplated hereby. 
 19.15 Third
Parties. Nothing in this Agreement, express or implied, is intended to confer upon any Person, including any insurer for the benefit of any of the Parties or such Parties’ Affiliates whether any such insurance relates to the subject matter
of this Agreement or otherwise, other than the Parties and their successors, any rights or remedies under or by reason of this Agreement. 
 19.16 Force Majeure. Any Party shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of
the prevention to the other Parties. Such excuse shall be continued so long as the condition constituting force majeure continues. For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including an
act of God, voluntary or involuntary compliance with any regulation, law or order of any government, war, terrorist action, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials
by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, any payment due and owing hereunder shall not be delayed by the payer because of a force majeure affecting the payer, unless such force majeure specifically precludes the
payment process. Any Party claiming relief pursuant to this Section 19.16 shall use commercially reasonable efforts to minimize the impact of such a force majeure. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 40 

 IN WITNESS WHEREOF, the Parties have executed this Agreement
in duplicate originals by their proper officers as of the date and year first above written. 
  

			
	MONOGRAM BIOSCIENCES, INC.
		
	By:	 	 /s/ William D. Young

	Name:	 	William D. Young
	Title:	 	Chief Executive Officer
	
	PFIZER INC.
		
	By:	 	 /s/ Marie-Caroline Sainpy

	Name:	 	Marie-Caroline Sainpy
	Title:	 	 Senior Vice President USP
 Marketing and Worldwide
Commercial Development

 ANNEX A 
 Performance Standards 
 Samples from Established Countries 
  

			
	 Assay Attribute
	 	 Performance Standards

	[*]	 	[*]
	[*]	 	 [*]
 [*]

	[*]	 	[*]
	[*]	 	[*]

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 A-1 

 ANNEX B 
 Monogram Copyrights 
 None. 
  

 B-1 

 ANNEX C 
 Monogram Patent Rights 
  

													
	Matter No.	 	Country	 	Application
No.	 	Filing
Date	 	Patent
No.	 	Issue
Date	 	Title
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 		 		 	[*]

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 C-1 

 ANNEX D 
 Sample Handling Guidelines 
 

 
 Procedure for Collection, Handling, and Shipment of Specimens 
 to Monogram Biosciences, Inc. for 
 Clinical Research/Pharma Collaborations Testing 
 (PhenoSenseTM HIV, GeneSeqTM HIV, PhenoSenseGTTM,
PhenoSenseTM Entry HIV, GeneSeqTM 
 Entry HIV, and Tropism Assays) 
 HIV RNA is especially vulnerable to degradation; therefore, proper collection and handling of blood specimens are essential for successful performance of these assays.

 Specimen Volume Requirements for all assays: 
  

	•	 	3.0 mL of frozen EDTA plasma (lavender top or PPT). 

  

			
	NOTE:	  	The PhenoSenseTM HIV, GeneSeqTM HIV, and PhenoSenseGTTM assays may be performed on the same 3 mL specimen. Only one specimen needs to be submitted if all assays are to be
performed. An additional 3 mL specimen must be submitted for the PhenoSenseTM Entry HIV, GeneSeqTM Entry HIV, and Tropism assays.
		
		  	The PhenoSenseTM HIV, GeneSeqTM HIV, and PhenoSenseGTTM assays are validated for testing specimens with HIV-1 viral loads equal to or greater than 500 copies/mL. The
PhenoSenseTM Entry HIV, GeneSeqTM Entry HIV, and Tropism assays require a minimum plasma HIV-1 viral load equal to or greater than 1,000 copies/mL.

 Specimen Collection and Processing: 
  

	•	 	Draw whole blood in a sterile tube containing EDTA anticoagulant (lavender top or PPT). 

  

	•	 	Centrifuge blood within 6 hours of collection at 1000-1200 x g at room temperature for 10-15 minutes. (PPT must be spun within two hours of collection.)

  

	•	 	Immediately transfer plasma to a screw-top plasma tube and freeze immediately at or below -20o C. (PPT should be frozen immediately after centrifugation at or below -20o C.) 

  

	•	 	DO NOT THAW SAMPLE AFTER FREEZING! 

 Specimen Packaging and
Shipping: 
  

	•	 	Plasma must be transported frozen on dry ice. Properly package specimens to ensure safe arrival to Monogram Biosciences. 

  

	•	 	Transportation of whole blood or plasma must comply with federal, state, county, and local regulations for the transport of infectious agents. 

  

	•	 	Enclose a completed sample list with patient information for each specimen with each shipment. 

  

	•	 	Notify Monogram Biosciences of specimen shipment by e-mail. E-mail the following information to -receiving@monogrambio.com 

  

	 	•	 	Number of specimens enclosed 

  

	 	•	 	Your name and phone number 

  

	 	•	 	Airbill number 

  

	 	•	 	Study name 

  

	 	•	 	Name of courier service 

  

	 	•	 	Ship specimens to Monogram Biosciences to allow for receipt on Monday through Saturday only. 

 If shipping on Friday, please check airbill for Saturday delivery. 
  

	•	 	If delivery will occur or be affected by a holiday, please call your Monogram Biosciences Project Manager at (650) XXX-XXXX to ensure proper delivery.

  

 D-1 

	•	 	Complete the airbill and prepare the package for shipment in compliance with Diagnostic Specimens IATA Packaging Instruction 650. Please note the IATA shipper’s
responsibility: The shipper is required to comply with the rules and guidelines for transport of Infectious Substances and to ensure that shipments comply with ICAO and IATA regulations. 

  

	•	 	If the HIV samples are cultured or amplified in any way, then ship the samples as infectious substances and include the Shipper’s Declaration of Dangerous Goods.

  

			
	 •        Ship all specimens to the following address: 
	 	Monogram Biosciences, Inc.
		 	345 Oyster Point Boulevard
		 	South San Francisco, CA 94080
		 	Attn: Project Manager
		 	Phone: (650) XXX-XXXX
		 	Fax: (650) 624-4457

  

 D-2 

 ANNEX E 
 Examples of Fulfillment Standards under Section 2.3 
  

			
	 US Coverage Levels
	 	 % Samples Covered by MGRM
 (evaluated quarterly)

	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	

  

							
	Scenario #1	 	 	 	 	 	Comments
	[*]	 	[*]	 		 	
	[*]	 		 	[% Tests]	 	
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	
				
	Scenario #2	 	 	 	 	 	 
				
	[*]	 	[*]	 		 	
				
	[*]	 		 	[*]	 	[*]
				
	[*]	 	[*]	 	[*]	 	
				
	[*]	 	[*]	 	[*]	 	
				
	[*]	 	[*]	 	[*]	 	
				
	Scenario #3	 	 	 	 	 	 
				
	[*]	 	[*]	 		 	
				
	[*]	 		 	[*]	 	[*]
				
	[*]	 	[*]	 	[*]	 	
				
	[*]	 	[*]	 	[*]	 	
				
	[*]	 	[*]	 	[*]	 	

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 E-1 

 ANNEX F 
  

					
		 	Pfizer:	  	Kate Robins
		 		  	860-732-9684
		 	Monogram:	  	Alfred G. Merriweather
		 		  	650 624 4576

 Pfizer and Monogram to Make HIV Co-Receptor Tropism Assay Available Globally 
 Understanding HIV’s co-receptor usage may facilitate targeting of drugs to appropriate patients 
 New York, NY and South San Francisco, CA, May 8, 2006 — Pfizer Inc. and Monogram Biosciences, Inc. announced today a non-exclusive collaboration to make Monogram’s HIV Co-Receptor Tropism Assay
available for patient use on a global basis. The assay is a diagnostic tool to show tropism – the path taken by the virus to access human CD4 cells. 
 Tropism information is intended to help identify patients who are most likely to respond to a class of investigational drugs known as CCR5 antagonists. CCR5 antagonists are designed to block viral cell entry through the CCR5 co-receptor.
Studies have shown that 80-85 percent of people newly diagnosed with HIV and previously untreated with HIV therapy have dominant CCR5-tropic virus. This drops to 50-60 percent in patients who have been treated before with anti-retroviral medicines.

 Pfizer has a CCR5 antagonist, maraviroc, in phase 3 development and has used the Monogram tropism assay to select patients for enrolment in late-stage
clinical studies. The agreement announced today expands this clinical trial collaboration and provides for global availability of Monogram’s assay in a multi-year collaboration. 
 “Because of the important role the Co-Receptor Tropism Assay is believed to play in CCR5 antagonist clinical development, we are pleased to be expanding our partnership with Pfizer. We look forward to
working together so that the right medicine can be made available to the right patients at the right time” said William D. Young, Monogram CEO. 
  

 F-1 

 Under the terms of the agreement announced today, Pfizer and Monogram will collaborate to make Monogram’s
Co-Receptor Tropism Assay available globally. Pfizer also entered into an agreement to invest $25 million in Monogram this month through a Senior Secured Convertible Note, payable in May 2010. The closing of the investment is subject to customary
closing conditions. 
 “CCR5 antagonists have a mechanism of action different from currently approved drugs,” said John LaMattina, president,
Pfizer Global Research and Development. “With this collaboration we are working to advance global access to new diagnostics that may better assess the potential for CCR5 antagonists to fulfill an unmet medical need.” 
 About Pfizer 
 Pfizer is committed to bringing meaningful
improvement to the lives of people living with HIV/AIDS and those at risk around the world. Our commitment is embodied in our products, partnerships, pipeline and philanthropy. 
 Pfizer Global Research & Development is the world’s largest privately owned biomedical research organization. Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for
humans and animals, and many of the world’s best-known consumer brands. 
 About Monogram 
 Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases
and cancer. The Company’s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company’s technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.monogrambio.com. 
  

 F-2 

 ANNEX G 
 Reports 
  

					
	Agreement
Section	 	Report	 	Frequency
	[*]	 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]
	[*]	 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]
	[*]	 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]
		 	[*]	 	[*]

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 G-1 

 ANNEX H 
 Third-Party Intellectual Property 
 License Agreement by and among Grantor and University of Iowa Research
Foundation, dated August 25, 2005, for Patent No. 5,168,062, titled “Transfer Vectors and Microorganisms Containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter DNA Sequence.” 
 License Agreement by and among Grantor and University of Iowa Research Foundation, dated August 25, 2005, for Patent No. 5,385,839, titled “Transfer
Vectors and Microorganisms Containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter DNA Sequence.” 
 License Agreement by and among Grantor and
NIH, dated January 1, 1996, for Patent No. 5,252,477, titled “Human Immunodeficiency Virus Specific Proteolytic Enzyme and a Method for its Synthesis and Renaturation.” 
 License Agreement by and among Grantor and NIH, dated January 1, 1996, for Patent No. 5,843,638, titled “Nucleic Acids and Peptides of Human
Immunodeficiency Virus Type-1 (HIV-1).” 
  

 H-1 

 ANNEX I 
 Maximum Number of Infrastructure Plans Per Calendar Year 
  

	•	 	[*] 

 [*] 
  

	•	 	[*] 

  

			
	[*] =	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

 I-1Collaboration Security Agreement

 EXHIBIT 10.42 
 COLLABORATION SECURITY AGREEMENT 
 This Collaboration Security Agreement (this
“Agreement”) is made and entered into as of May 5, 2006 by and between Monogram Biosciences, Inc. (the “Grantor”), and Pfizer Inc. (the “Secured Party”). 
 RECITALS 
 The Secured
Party proposes to enter into a transaction with the Grantor pursuant to a Collaboration Agreement dated as of the date hereof (as amended from time to time, the “Collaboration Agreement”), between the Grantor and Secured Party.
Grantor wishes to secure performance of certain specified obligations to Secured Party under the Collaboration Agreement and this Agreement with certain of its assets. 
 NOW, THEREFORE, the Grantor and the Secured Party agree as follows: 
 1. Definitions 
 1.1 Unless otherwise defined herein, terms defined in the Collaboration
Agreement and used herein shall have the meanings given to them in the Collaboration Agreement, and all terms used herein that are defined in Article 9 of the Code (as defined below) and not otherwise defined herein shall have the same meaning as
set forth in the Article 9 of the Code. 
 1.2 The following terms shall have the following meanings: 
 (a) “Agreement” has the meaning assigned to it in the Recitals. 
 (b) “Code” means the Uniform Commercial Code as from time to time in effect in the State of New York. 
 (c) “Collateral” has the meaning assigned to it in Section 2.1 
 (d) “Copyright Licenses” means all license agreements of the Grantor providing for the grant to the Grantor of any right to use
any Copyright by the Grantor, and the right to prepare for sale, sell and advertise for sale, all Inventory now or hereafter covered by such licenses. 
 (e) “Copyrights” means all copyrights arising under the laws of the United States, the European Union or any other country or any political subdivision thereof, whether or not the underlying
works of authorship have been published or registered, all US or other copyright registrations and copyright applications, including, without limitation, any copyright registrations and copyright applications, and all renewals thereof, (ii) all
income, royalties, damages and payments now and hereafter due and/or payable with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past or future
infringements thereof and (iii) the right to sue or otherwise recover for past, present and future infringements thereof. 

 (f) “Event of Default” means the occurrence of any of the following: 

(i) any breach by Grantor of the Secured Obligations referred to clause (x) of such definition (it being understood, for the avoidance of
doubt, that for purposes of this Security Agreement, without limiting any other circumstance that would constitute a breach of such Secured Obligations (A) such obligations shall be deemed breached in the event Section 13.1 of the
Collaboration Agreement is held by a court of competent jurisdiction to be unenforceable but (B) such obligations shall not be deemed breached in the event the Secured Party elects pursuant to Section 365(n)(1)(A) of the Bankruptcy Code to
terminate the license granted pursuant to Section 13.1 of the Collaboration Agreement or fails to elect to retain or otherwise use commercially reasonable efforts to preserve, under Section 365(n) of the Bankruptcy Code, its rights under
the license granted pursuant Section 13.1 of the Collaboration Agreement, or 
 (ii) the Grantor fails to cure within 60 days
following notice any breach of the Secured Obligations referred to in clause (y) of such definition, to the extent such breach materially impacts the rights or remedies of the Secured Party hereunder. 
 (g) “Grantor” has the meaning assigned to it in the preamble. 
 (h) “Intellectual Property” means, collectively, the Copyrights, Copyright Licenses, Patents, Patent Licenses, Trade Secrets,
Trademarks and Trademark Licenses, including but not limited to the Monogram Copyrights, Monogram Patents Rights, Monogram Trademarks, Monogram Technology, Monogram Confidential Information and Tangible Materials. 
 (i) “Intellectual Property Collateral” means all Intellectual Property and other assets or properties in which a security
interest is granted to Secured Party pursuant to Section 2.1. 
 (j) “Lien” means any lien, charge, claim,
pledge, security interest, conditional sale agreement or other title retention agreement, lease, mortgage, security agreement, option or other encumbrance (including but not limited to the filing of, or agreement to give, any financing statement
under the UCC (as defined below), and excluding any non-exclusive license). 
 (k) “Material Adverse Effect” has the
meaning assigned to it in Section 3.1. 
 (l) “Patent Licenses” means all license agreements of the Grantor
with any other Person, in connection with such other Person’s patents, where the Grantor is a licensee under any such agreement and the right to prepare for sale, sell and advertise for sale, all Inventory now or hereafter covered by such
licenses. 
 (m) “Patents” means all patents of the United States, the European Union or any other country or
political subdivision thereof, all applications for patents of the United States, the European Union or any other country or political subdivision thereof and all patentable inventions and all reissues and extensions thereof, including, without
limitation, all 
  

 2 

 patents and patent applications, and including, without limitation, (i) all inventions and improvements described
and claimed therein, (ii) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations thereof, (iii) all income, royalties, damages and other payments now and hereafter due and/or
payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages and payments for past, present or future infringements thereof), and (iv) all other rights corresponding
thereto in the United States, the European Union or any other country or political subdivision thereof and all reissues, divisions, continuations, continuations-in-part, substitutes, renewals, and extensions thereof, all improvements thereon, and
all other rights of any kind whatsoever accruing thereunder or pertaining thereto. 
 (n) “Permitted Liens” means
Liens that are granted after the date hereof and are junior and expressly subordinated to the security interest of the Secured Party granted hereunder pursuant to an intercreditor agreement reasonable satisfactory to the Secured Party
(iii) Liens for taxes, fees and other governmental charges, either not delinquent or being contested in good faith by appropriate proceedings and for which the Grantor maintains adequate reserves, (iv) Liens arising from judgments
resulting from circumstances that do not constitute an Event of Default, (v) Liens in favor of financial institutions in connection with the Grantor’s deposit accounts securing standard fees for deposit, lockbox and other services (but not
borrowed money), (vi) Liens of materialmen, carriers, mechanics or similar Liens arising in the ordinary course of business, (vii) Deposits in the ordinary course of business under worker’s compensation and other similar laws,
(viii) Liens arising under that certain Note Security Agreement of even date herewith between Grantor and Secured Party (the “Note Security Agreement”), and (viii) Liens in favor of customs authorities arising as a matter
of law. 
 (o) “Person” means an individual, partnership, corporation (including a business trust), limited
liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof. 
 (p) “Purchase Agreement” means the Note Purchase Agreement, dated as of May 5, 2005, between Grantor and Secured Party. 
 (q) “Secured Obligations” means all obligations and liabilities of the Grantor to the Secured Party, whether direct or
indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with (x) Section 13.1 of the Collaboration Agreement (including the obligation to make available
to the Secured Party the rights granted pursuant to Section 13.1 of the Collaboration Agreement and the right of the Secured Party to exercise such rights at the times and in the manner contemplated by such Section 13.1) or (y) this
Agreement. 
 (r) “Trade Secrets” means all trade secrets in the United States, the European Union, or any other
country or political subdivision thereof, including, without limitation, know-how, processes, formulae, compositions, designs, and confidential business and technical information, and all rights of any kind whatsoever accruing thereunder or
pertaining thereto, including, without limitation, (i) all income, royalties, damages and payments now and hereafter due and/or payable with respect thereto, including, without limitation, payments under 
  

 3 

 all licenses, non-disclosure agreements and memoranda of understanding entered into in connection therewith, and damages
and payments for past or future misappropriations thereof, and (ii) the right to sue or otherwise recover for past, present or future misappropriations thereof. 
 (s) “Trademark Licenses” means all license agreements of the Grantor with any other Person in connection with such other Person’s names or trademarks, where the Grantor is a licensee under
any such agreement and the right to prepare for sale, sell and advertise for sale, all Inventory now or hereafter covered by such licenses. 
 (t) “Trademarks” means all trademarks, service marks, trade names, trade dress or other indicia of trade origin or business identifiers, trademark and service mark registrations, and applications for trademark or
service mark registrations, whether in the United States Patent and Trademark Office or any similar office or agency of the United States, any State thereof or any other country or the European Union, or any political subdivision thereof (except for
“intent to use” applications for trademark or service mark registrations filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, unless and until an Amendment to Allege Use or a Statement of Use under Sections
1(c) and 1(d) of said Act has been filed) and all goodwill associated therewith, and any renewals thereof, including, without limitation, (i) the right to sue or otherwise recover for any and all past, present and future infringements or
dilutions thereof, (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto (including, without limitation, payments under all licenses entered into in connection therewith, and damages
and payments for past or future infringements or dilutions thereof), and (iii) all other rights corresponding thereto and all other rights of any kind whatsoever accruing thereunder or pertaining thereto, together in each case with the goodwill
of the business connected with the use of, and symbolized by, each such trademark, service mark, trade name, trade dress or other indicia of trade origin or business identifiers. 
 (u) “Transaction Documents” means, collectively, the Collaboration Agreement and this Agreement. 
 (v) “UCC” means the Uniform Commercial Code of any jurisdiction or any comparable law or system in any jurisdiction outside the
United States. 
 1.3 Other Definitional Provisions The words “hereof”, “herein”, “hereto” and
“hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section, Schedule, Exhibits and Annex references are to this Agreement
unless otherwise specified. Any reference in this Agreement to a Schedule or Annex shall refer to such Schedule or Annex as amended from time to time pursuant to the terms of this Agreement. 
 (b) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms. 
 2. Grant of Security Interest 
 2.1
Grant of Security Interest. As security for the prompt and complete performance when due (whether at the stated due date, declaration of default or breach, or otherwise) of the Secured Obligations, the Grantor hereby assigns, pledges and grants
to the 
  

 4 

 Secured Party, a security interest in all of the following property now owned or at any time hereafter acquired by the
Grantor or in which the Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Collateral”): 
 (a) all Monogram Technology, Monogram Patent Rights, Monogram Copyrights, Monogram Confidential Information and Monogram Trademarks; 
 (b) to the extent not otherwise described above, (x) all Tangible Material, and (y) all books and records pertaining to any of the
foregoing Collateral; 
 2.2 Further Identification of Collateral. Grantor shall promptly identify to Secured Party any assets or
property of the Grantor included within the Collateral on the date hereof or acquired after the date hereof which in its good faith judgment constitute Monogram Technology, Monogram Patent Rights, Monogram Copyrights and Monogram Trademarks and will
furnish to the Secured Party from time to time statements and schedules further identifying and describing such assets and property of the Grantor, as reasonably requested by the Secured Party. 
 2.3 No Liability of Secured Party under Licenses. The Secured Party shall not have any obligation or liability under any Copyright License, Patent
License or Trademark License by reason of or arising out of this Agreement or the receipt by the Secured Party of any performance or payment relating to such license pursuant hereto, nor shall the Secured Party be obligated in any manner to perform
any of the obligations of the Grantor under or pursuant to any such license, to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party under
any such license, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time. 
 3. Grantor’s Representations and Warranties. Grantor represents and warrants as follows: 
 3.1 Organization and Good Standing. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws
of the State of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as described in the SEC Documents (as defined in the Purchase Agreement), and is duly qualified as a foreign corporation and in
good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse
effect on the business, properties, financial condition or results of operations of the Grantor or to perform its obligations under the Collaboration Agreement and this Agreement (any of the foregoing, a “Material Adverse Effect”).

 3.2 Authorization. Grantor has authority and has obtained all approvals and consents necessary to enter into and deliver this
Agreement and carry out and perform all of its obligations hereunder. This Agreement constitutes a legal, valid and binding obligation of the Grantor, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy,

  

 5 

 insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights
generally and (ii) as limited by equitable principles generally, including any specific performance. 
 3.3 Compliance with Other
Instruments. The execution, delivery and performance of and compliance with this Agreement by the Grantor and any exercise of rights by the Secured Party thereunder will not conflict with or result in a breach or violation of the terms,
conditions or provisions of, or result in any acceleration or loss of rights under (including upon the passage of time or notice or both) (a) the Certificate of Incorporation or Bylaws of the Grantor, (b) any statute, law, rule or
regulation (including without limitation, the rules and regulations applicable to the Nasdaq Stock Market and applicable securities laws) applicable to the Grantor, (c) any state or federal order, judgment or decree applicable to the Grantor or
(d) any indenture, mortgage, lease or other agreement or instrument to which the Grantor or any of its properties is subject and, in the case of clauses (b), (c) or (d), where such breach or violation would have a Material Adverse Effect
or would materially impair or limit the exercise of rights by the Secured Party granted under any of the Transaction Documents. The execution, delivery and performance of and compliance with this Agreement will not require the approval of its
stockholders, or result in the creation or imposition of any Lien (other than Liens created hereunder) upon any of the properties or assets of the Grantor. 
 3.4 Title. Except for Permitted Liens, Grantor owns each item of Collateral free and clear of any and all Liens, encumbrances and other security interests, except for the security interest granted to the
Secured Party pursuant to this Agreement. No security agreement, financing statement or other public notice similar in effect with respect to all or any part of the Collateral is on file or of record in any public office, except such as may have
been filed in favor of the Secured Party pursuant to this Agreement or the Note Security Agreement. 
 3.5 Perfected First Priority
Liens. (i) The security interest granted hereby constitutes, or with respect to Collateral acquired after the date hereof, will constitute, a valid, binding and enforceable security interest in the Collateral, in favor of the Secured Party.

 (ii) Except for Permitted Liens (excluding for this purpose Liens permitted by clause (ii) of the definition of Permitted Liens
herein), the Liens granted to the Secured Party pursuant to this Agreement (upon filing of the Filings) will constitute perfected Liens on the Collateral prior to all other Liens on the Collateral. 
 3.6 Consents. No authorization, consent or approval or other action by, and no notice to or filing with, any Governmental Authority or other
regulatory body, or any other Person, is required for (i) the grant by Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral or (ii) the exercise by Secured Party of any of its rights and
remedies hereunder, except (A) for the filing of financing statements under the Article 9 of the Code (the “UCC Filings”), (B) with respect to the perfection of the security interest created hereby in Copyrights,
Trademarks or Patents, for the recording of this Agreement or a notice thereof, in the United States Patent and Trademark Office or the United States Copyright Office, as applicable (the “IP Filings” and, together with the UCC
Filings, the “Filings”), and (C) with respect to the perfection of the security interest created hereby in Collateral located outside of the United States, for registrations and filings in jurisdictions located outside of the
United States and covering rights in such jurisdictions in relation to such Collateral. 
  

 6 

 3.7 Names; Jurisdiction of Organization; Collateral Locations. Grantor is a Registered
Organization organized under the laws of the State of Delaware and Grantor’s (i) exact legal name, as such name appears in its respective certificate of incorporation or any other organizational document, (ii) organizational
identification number, if any, (iii) the location of Grantor’s chief executive office or sole place of business in the last 6 months, (iv) any other corporate or organizational names any Grantor has had in the past five years,
together with the date of the relevant change, (v) any United States trade names of such Granting Party, together with the states of the United States in which such trade names are used and (vi) all jurisdiction in which a Uniform
Commercial Code financing statement may have been filed under applicable law (as in effect prior to, on or after July 1, 2001) to perfect the personal property collateral of the Company are specified on Schedule 1. 
 4. Covenants. Grantor covenants and agrees with the Secured Party that so long as any Secured Obligations remain outstanding it will (without
limiting the effect of any and all covenants set forth in the Collaboration Agreement) comply with the following: 
 4.1 Payment of
Obligations. The Grantor will pay and discharge or otherwise satisfy at or before maturity or before they become delinquent, as the case may be, all taxes, assessments and governmental charges or levies imposed upon or affecting the Collateral
of Grantor, as well as all claims of any kind (including, without limitation, claims for labor, materials and supplies) against or with respect to such Collateral, except (a) that no such charge need be paid if the amount or validity thereof is
currently being contested in good faith by appropriate proceedings, reserves in conformity with GAAP with respect thereto have been provided on the books of the Grantor or (b) where the failure to pay, discharge or otherwise satisfy such
obligations could not, individually or in the aggregate, reasonably be expected to result in the sale, forfeiture or loss of any portion of the Collateral or any interest therein. 
 4.2 Maintenance of Perfected Security Interest. The Grantor shall maintain the security interest created by this Agreement as a valid security
interest having at least the priority described in Section 3.5 and shall defend such security interest against the claims and demands of all Persons whomsoever. 
 4.3 Notices. The Grantor will advise the Secured Party promptly, in reasonable detail of any of the occurrences described below and will and deliver to the Secured Party all additional executed financing
statements and other documents reasonably requested by the Secured Party to maintain the validity, perfection and priority of the security interests provided for herein: 
 (a) The creation or existence of any Lien (other than security interests created hereby) on any of the Collateral; 
 (b) the occurrence of any other event which could reasonably be expected to have a material adverse effect on the aggregate value of the Collateral or on the security interests created hereby; 
 (c) any change of its jurisdiction of organization or the location of its chief executive office or sole place of business from that referred to
in Section 3.7; or 
  

 7 

 (d) any change of its name. 
 4.4 Intellectual Property. (a) The Grantor agrees to take all reasonably necessary steps, including in the United States Patent and Trademark
Office or in any court, to: 
 (i) maintain each trademark registration and each Trademark License constituting Collateral, as the
case may be, except, in each case in which the Grantor has reasonably determined that any of the foregoing is not of material economic value to it, and 
 (ii) pursue each trademark application constituting Collateral, including, without limitation, the filing of responses to office actions issued by the United States Patent and Trademark Office, the filing of
applications for renewal, the filing of affidavits under Sections 8 and 15 of the United States Trademark Act, and the participation in opposition, cancellation, infringement and dilution proceedings, except, in each case in which the Grantor
has reasonably determined that any of the foregoing is not of material economic value to it. The Grantor agrees to take corresponding steps with respect to each new or acquired trademark or service mark registration, or application for trademark or
service mark registration, or any rights obtained under any Trademark License, in each case, to which it is now or later becomes entitled, except in each case in which the Grantor has reasonably determined that any of the foregoing is not of
material economic value to it. Any expenses incurred in connection with such activities shall be borne by the Grantor. 
 (b) The
Grantor agrees to take all necessary steps, including in the United States Patent and Trademark Office or in any court, to: 
 (i)
maintain each patent and each Patent License constituting Collateral, including but not limited to the Monogram Patent Rights now or hereafter identified on Annex C of the Collaboration Agreement, except in case the Grantor has reasonably
determined that any of the foregoing is not of material economic value to it, and 
 (ii) pursue each patent application,
constituting Collateral, including but not limited to those now or hereafter identified in Annex C of the Collaboration Agreement including the filing of divisional, continuation, continuation-in-part and substitute applications, the filing of
applications for reissue, renewal or extensions, the payment of maintenance fees, and the participation in interference, reexamination, opposition or infringement and misappropriation proceedings, except, in each case in which the Grantor has
reasonably determined that any of the foregoing is not of material economic value to it. The Grantor agrees to take corresponding steps with respect to each new or acquired patent, patent application, or any rights obtained under any Patent License,
in each case, which it is now or later becomes entitled, except in each case in which the Grantor has reasonably determined that any of the foregoing is not of material economic value to it. Any expenses incurred in connection with such activities
shall be borne by the Grantor. 
 (c) The Grantor shall take all additional steps not set forth in subsections (a) and
(b) hereof which it or the Secured Party deems reasonably appropriate under the circumstances to preserve and protect its material Copyrights, Copyright Licenses, Trademarks, Trademark Licenses, Patents and Patent Licenses constituting the
Collateral. 
  

 8 

 (d) The Grantor shall not abandon any trademark registration, patent or any pending trademark or
patent application, constituting Collateral, including but not limited to those now or hereafter listed on Annex C of the Collaboration Agreement, without the written consent of the Secured Party, unless the Grantor shall have previously determined
that such use or the pursuit or maintenance of such trademark registration, patent or pending trademark or patent application is not of material economic value to it. 
 (e) Subject to the Grantor’s reasonable business judgment, the Grantor (either itself or through licensees) will not (and will not permit any licensee or sublicensee thereof to) do any act or knowingly
omit to do any act whereby any material Copyrights, Patents or Trademarks constituting Collateral may become invalidated or otherwise impaired. Subject to the Grantor’s reasonable business judgment, the Grantor will not (either itself or
through licensees) do any act whereby any material portion of the Copyrights constituting Collateral may fall into the public domain. 
 (f) The Grantor will notify the Secured Party promptly if it knows, or has reason to know, that any application or registration relating to any material Patents, Trademarks or Copyrights constituting Collateral may become forfeited,
abandoned or dedicated to the public, or of any adverse determination or development (including, without limitation, the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office,
the United States Copyright Office or any court or tribunal in the European Union or any other country) regarding the Grantor’s ownership of, or the validity of, any material Intellectual Property Collateral or the Grantor’s right to
register the same or to own and maintain the same. 
 (g) Whenever the Grantor, either by itself or through any agent, employee,
licensee or designee, shall file an application for the registration of any Patent, Trademark or Copyright that would constitute Collateral with the United States Patent and Trademark Office, the United States Copyright Office or any similar office
or agency in the European Union, any other country or any political subdivision thereof, the Grantor shall report such filing to the Secured Party within ten Business Days after the last day of the fiscal quarter in which such filing occurs. The
Grantor shall (x) make all appropriate filings in the United States Patent and Trademark Office or the United States Copyright Office and any applicable office(s) outside of the United States for the registration of Intellectual Property
constituting Collateral owned outside of the United States and filing of financing statements under the Uniform Commercial Code of any applicable jurisdiction and any similar registration system outside of the United States, (y) execute and
deliver, and have recorded, any and all agreements, instruments, documents, and papers as the Secured Party may reasonably request (including but not limited to amendments and supplements to Annexes B and C to the Collaboration Agreement further
identifying and describing the Intellectual Property Collateral and (z) take any other action reasonably requested by the Secured Party, to evidence the Secured Party’s security interest in any Copyright, Patent or Trademark of Grantor
relating thereto or represented thereby and to perfect the security interest granted to the Secured Party therein to the extent provided in respect of Copyrights, Patents or Trademarks constituting Collateral on the date hereof. 
  

 9 

 (h) Grantor will take all reasonable and necessary steps, including, without limitation, in any
proceeding before the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the
relevant registration) and to maintain each registration of all material Intellectual Property Collateral, including, without limitation, filing of applications for renewal, affidavits of use and affidavits of incontestability. 
 4.5 Encumbrances. Except for Permitted Liens, the Grantor shall not grant a security interest in any of the Collateral other than to Secured Party
or execute any financing statements covering any of the Collateral in favor of any person other than Secured Party. 
 4.6 Limitations on
Dispositions of Collateral. Without the prior written consent of the Secured Party, the Grantor will not sell, assign, transfer, exchange, grant exclusive licenses with respect to (other than compulsory licenses) or otherwise dispose of, or
grant any option with respect to the Collateral, or attempt, offer or contract to do so (any of the foregoing, a “Transfer”), except to the extent granting a Permitted Lien would constitute such disposition, provided that the
foregoing shall not restrict a Transfer if (i) the Transferee agrees to comply with the obligations hereunder as they relate to the transferred Collateral and (ii) delivers a written notice to Secured Party acknowledging the existence and
priority of the security interest of Secured Party in the Collateral and agreeing to recognize the continued validity of the license to the Secured Party pursuant to Section 13.1 of the Collaboration Agreement. 
 4.7 Fees and Costs. After the occurrence of an Event of Default, the Grantor shall pay all expenses, including reasonable attorneys’ fees,
incurred by Secured Party in the preservation, realization, enforcement or exercise of any Secured Party’s rights under this Agreement. 
 4.8 Further Assurances. At any time and from time to time, upon the written request of Secured Party, and at the sole expense of the Grantor, the Grantor shall promptly and duly execute and deliver any and all such further
instruments and documents and take such further action as Secured Party may reasonably deem desirable to obtain the full benefits of this Agreement and of the rights and powers herein granted, including, without limitation, (a) to secure all
consents and approvals necessary or appropriate for the grant of a security interest to Secured Party in any Collateral held by the Grantor or in which the Grantor has any rights not heretofore assigned, (b) filing any financing or continuation
statements or amendments thereof under the Uniform Commercial Code (or other similar laws) in effect in any jurisdiction with respect to the security interests granted hereby, (c) furnishing to Secured Party from time to time statements and
schedules further identifying and describing the Collateral and such other reports in connection with the Collateral, in each case, as Secured Party may reasonable request and (d) if any Collateral shall be in the possession of a Third Party,
notifying such party of Secured Party’s security interest created hereby and, at Secured Party’s option, obtaining a written acknowledgment from such party that it holds possession of the Collateral for the benefit of Secured Party.

 4.9 Authorization to File Financing Statements. Without limiting the generality of the foregoing, the Grantor hereby authorizes and
approves of Secured Party’s 
  

 10 

 preparing, filing and/or recording, with, on behalf of or without Grantor or its signature, and promptly upon Secured
Party’s request the Grantor shall sign and execute together, alone or with Secured Party, all as Secured Party shall reasonably determine, any financing statement or other comparable filing (including but not limited to, any such financing
statements as required by the UCC in any jurisdiction or any similar documents required to be filed in other jurisdictions or other comparable filings at the United States Patent and Trademark Office, the United States Copyright Office or any
similar governmental authority in other jurisdictions) that (A) describe or identify the Collateral by type or in any other manner as Secured Party may determine, regardless of whether any particular asset of Grantor falls within the scope of
Article 9 of the Code or whether any particular asset of Grantor constitutes part of the Collateral, and (B) contain any other information required by Part 5 of Article 9 of the Code or any applicable UCC for the sufficiency or filing office
acceptance of any financing statement, continuation statement or amendment) or take such other additional actions as Secured Party may reasonably require to perfect or protect the rights and interests of Secured Party in the Collateral. Until the
termination of this Agreement, Grantor hereby irrevocably appoints Secured Party as its agent to execute such documents or take such other action as is reasonably necessary to perfect or protect Secured Party’s rights and interests in the
Collateral in accordance with this Agreement. 
 4.10 Further Information. At all times Grantor shall provide to Secured Party all
information that is reasonably requested and necessary for Secured Party to perfect its security interests and Liens in the Collateral. 
 4.11 No Duties of Secured Party. Anything herein to the contrary notwithstanding, (i) the exercise by Secured Party of any of its rights hereunder shall not release Grantor from any of its obligations in respect of the
Collateral, and (ii) Secured Party shall not have any obligation or liability by reason of this Security Agreement with respect to any of the Collateral, nor shall the Secured Party be obligated to perform any of the obligations or duties of
Grantor or to take any action to collect or enforce any claim for payment assigned hereunder. 
 5. Remedies on Default. If an Event
of Default shall occur and be continuing, the Secured Party may, at its option, in addition to any rights, privileges, powers and remedies provided by law: 
 (a) foreclose or otherwise enforce Secured Party’s security interests and Liens or other rights and interests in the Collateral in any manner permitted by law or provided for in this Security Agreement;

 (b) sell or otherwise dispose of the Collateral or any part thereof or interest therein at one or more public or private sales at
Secured Party’s place of business or any other place or places, whether or not such Collateral is present at the place of sale, for cash or credit or future delivery, on such terms and in such manner as Secured Party may reasonably determine;
for the avoidance of doubt, Secured Party may, in its own name, or in the name of a designee or nominee, buy the Collateral at any public sale, and, if permitted by applicable law, at any private sale. 
 (c) use, operate, consume and sell the Collateral in its possession as appropriate for the purpose of performing the Grantor’s obligations
with respect thereto to the extent necessary to satisfy the obligations of the Grantor. 
  

 11 

 (d) recover from the Grantor the reasonable costs and expenses (including, attorneys’ fees)
incurred or paid by the Secured Party in exercising any right, power or remedy provided by law or this Security Agreement (including, the reasonable costs and expenses incurred in assembling, taking, improving or selling the Collateral or any part
thereof); 
 (e) require the Grantor to promptly assemble the Collateral and all information, books, records, and other materials
relating to the Collateral and make such available to Secured Party at a place to be designated by Secured Party; 
 (f) enter onto
the property where any Collateral is located and take possession thereof with or without judicial process; 
 (g) cure any breach,
default or improper termination of any agreement, contract, lease or license of the Grantor that is included or encompassed in the Collateral; 
 (h) substitute itself for the Grantor in any proceeding or lawsuit included or encompassed within, arising from, related to or connected with the Collateral or Secured Party’s rights and interests in it or commence, on behalf of
the Grantor and in the Grantor’s name, any proceeding or lawsuit to protect the Collateral or Secured Party’s rights and interests in it; and 
 (i) prepare any Collateral for disposition in any manner and to the extent the Secured Party deems appropriate. The Grantor shall be given ten (10) business days prior written notice of the time and place
of any public sales or of the time after which any private sales or other intended dispositions are to be made, which notice the Grantor hereby agrees shall be deemed reasonable notice thereof; provided, however, Secured Party shall not be required
to give such notice in the case of any Collateral that the Secured Party in good faith determines to be declining speedily in value. The Secured Party shall not be obliged to make any sale of Collateral regardless of notice of sale having been
given, the Secured Party may adjourn any public or private sale from time to time by announcement at the time and place fixed therefore, and such sale may, without further notice, be made at the time and place it was so adjourned. Upon any sale or
other disposition pursuant to this Security Agreement, the Secured Party shall have the right to deliver, assign, and transfer to the purchaser thereof the Collateral or portion thereof so sold or disposed of by the Secured Party. Each purchaser at
any such sale or other disposition (including the Secured Party) shall hold the Collateral free from any claim or right of whatever kind, including any equity or right of redemption of the Grantor. 
 (j) subject to preexisting rights and licenses and applicable law, license or sublicense, as applicable, whether on an exclusive or non-exclusive
basis, any Intellectual Property Collateral owned by or licensed to the Grantor for such term and on such conditions and in such manner as the Secured Party shall in its sole judgment determine. 
 (k) If the Grantor fails to perform or comply with any of its agreements contained herein, after the occurrence and during the continuance of an
Event of Default, the Secured Party, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement. 
  

 12 

 5.2 Application of Proceeds. All payments received and amounts realized by Secured Party shall be
promptly applied and distributed by the Secured Party in the following order of priority: 
 (i) first, to the payment of all costs
and expenses, including reasonable legal expenses and attorneys fees, incurred or made hereunder by Secured Party, including any such costs and expenses of foreclosure or suit, if any, and of any sale or the exercise of any other remedy under this
Section 6, and of all taxes, assessments or liens superior to the lien granted under this Agreement; and 
 (ii) second, to the
payment or satisfaction to Secured Party of the amounts and obligations then owing under or pursuant to the Collaboration Agreement or this Agreement (including, without limitation, pursuant to a claim for damages). 
 5.3 Deficiency. The Grantor shall be liable for any deficiency if the proceeds of any sale or other disposition of the Collateral are insufficient
to pay the Secured Obligations and the fees and disbursements of any attorneys employed by the Secured Party or to collect such deficiency. 
 5.4 No Duty of Secured Party. The powers conferred upon the Secured Party hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the safe custody
of any Collateral in its possession and the accounting for moneys actually received by it hereunder, shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights
pertaining to any Collateral. Grantor hereby agrees to indemnify the Secured Party against all losses, resulting from any breach of Grantor’s representations, warranties, covenants or agreements under this Agreement. 
 5.5 Power of Attorney. Grantor hereby irrevocably appoints the Secured Party, effective only upon the occurrence and during the continuance of an
Event of Default, as its attorney-in-fact and proxy, with full authority in the place and stead of Grantor and in the name of Grantor or otherwise, from time to time in the Secured Party’s discretion, to take any action and to execute any
instrument which the Secured Party may deem reasonably necessary or advisable to accomplish the purposes of this Agreement including (i) to ask, demand, collect, sue for, recover, compound, receive and give acquaintance and receipts for moneys
due and to become due under or in respect of any Collateral, (ii) to receive, endorse, and collect any drafts or other instruments, documents and chattel paper in connection with clause (i) above, (iii) to file any claims or take any
action or institute any proceedings which the Secured Party may reasonably deem necessary or desirable to enforce the rights of the Secured Party with respect to any Collateral, (iv) with respect to any Intellectual Property Collateral of the
Grantor, execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Secured Party may request to evidence the Secured Party’s security interest in such Intellectual Property Collateral and the
goodwill and general intangibles of Grantor relating thereto or represented thereby; and (vi) to execute assignments, licenses and other documents to enforce the rights of the Secured Party with respect to any Collateral. This power shall be
coupled with an interest and shall be irrevocable until the date on which all of the Secured Obligations have been satisfied and performed in full upon the termination of this Agreement. 
  

 13 

 5.6 Remedies Cumulative. The Secured Party’s rights and remedies under this Agreement, the
Collaboration Agreement, and all other agreements shall be cumulative. The Secured Party shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law, or in equity. No exercise by the Secured Party of one
right or remedy shall be deemed an election, and no waiver by the Secured Party of any Event of Default on Grantor’s part shall be deemed a continuing waiver. No delay by Secured Party shall constitute a waiver, election, or acquiescence by it.
No waiver by the Secured Party shall be effective unless made in a written document signed on behalf of the Secured Party and then shall be effective only in the specific instance and for the specific purpose for which it was given. 
 6. NOTICES; LICENSE TO GRANTOR 
 6.1 Notices. Unless otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall be in writing and (except for financial
statements and other informational documents which may be sent by first-class mail, postage prepaid) shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by
telefacsimile to the Grantor or to the Secured Party, as the case may be, at its addresses set forth below: 
  

			
	For Monogram:	  	Monogram Biosciences Inc.
		  	345 Oyster Point Boulevard
		  	South San Francisco, California 94080
		
		  	Attention: Chief Executive Officer
		  	Facsimile No: +1 650-635-1111
		
	with a copy to:	  	Attention: General Counsel
		  	Facsimile No.: +1 650-635-1111
		
	For Pfizer:	  	Pfizer Inc.
		  	235 East 42nd Street
		  	New York, New York 10017
		
		  	Attention: President, Pfizer Human Health
		  	Facsimile No.: +1 212-808-8652
		
	with a copy to:	  	Attention: Vice Chairman, Executive Vice President and General Counsel
		  	Facsimile No.: +1 212-808-8924

 The parties hereto may change the address at which they are to receive notices hereunder, by
notice in writing in the foregoing manner given to the other. 
  

 14 

 6.2 License to Grantor. In the event that following an Event of Default, the Secured Party
acquires any of the Collateral, the Secured Party shall be deemed to have thereupon granted to the Grantor an irrevocable, non-exclusive license or sublicense, as applicable (exercisable without payment of royalty or other compensation to the
Secured Party) to use, assign, license or sublicense such Collateral acquired by the Secured Party following an Event of Default (which obligation shall be without regard to, and not subject to or conditioned by, any claim of offset, setoff,
recoupment, or other claim of Secured Party). 
 7. GOVERNING LAW 
 This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of law. 
 8. SUBMISSION TO JURISDICTION 
 8.1
Submission to Jurisdiction. In accordance with Section 5-1402 of the New York General Obligations Law, the Grantor hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the Supreme
Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this
Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State
court or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in
any other manner provided by law. Nothing in this Agreement shall affect any right that the holder may otherwise have to bring any action or proceeding relating to this Agreement against the grantor or its properties in the courts of any
jurisdiction. 
 8.2 Waiver of Venue and Inconvenient Forum. The Grantor hereby irrevocably and unconditionally waives, to the fullest
extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any court referred to in Section 8.1. Each of
the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
 8.3 Service of Process. Grantor irrevocably consents to service of process in the manner provided for notices in Section 6.1. This
Section 8.3 does not affect any other method of service allowed by law. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law. 
 8.4 WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY
JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE 
  

 15 

 TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO
(A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT
IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.4. 
 8.5 Successors and Assigns. This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each of the parties (and for the avoidance of doubt references herein to a
Party shall also be deemed to also refer to successors and assigns); provided, however, that neither this Agreement nor any rights hereunder may be assigned by Grantor without the Secured Party’s prior written consent, which consent may be
granted or withheld in the Secured Party’s sole discretion. The Secured Party shall have the right without the consent of or notice to Grantor to sell, transfer, negotiate, or grant participation in all or any part of, or any interest in, the
Secured Party’s obligations, rights and benefits hereunder. 
 8.6 Severability of Provisions. Each provision of this Agreement
shall be severable from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision. 
 8.7 Amendments in Writing, Integration. This Agreement cannot be amended or terminated orally. All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect to the subject
matter of this Agreement, if any, are merged into this Agreement. 
 8.8 Counterparts. This Agreement may be executed in any number of
counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. 
  

 16 

 IN WITNESS WHEREOF, the parties have executed this Agreement
on the date set forth above. 
  

			
	GRANTOR
	
	MONOGRAM BIOSCIENCES, INC.
		
	By:	 	 /s/ William D. Young

	Name:	 	William D. Young
	Title:	 	Chief Executive Officer
	
	SECURED PARTY
	
	PFIZER INC.
		
	By:	 	 /s/ Marie-Caroline Sainpy

	Name:	 	Marie-Caroline Sainpy
	Title:	 	 Senior Vice President USP
 Marketing and Worldwide
Commercial Development

  

 Collaboration Security Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]